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ABSTRACT
Oxidative and proteotoxic stress are common hallmarks of Neurodegenerative diseases
(NDs). Cellular proteostasis is maintained through Heat shock protein (Hsp) 90 and Stressinducible protein 1 (STIP1) modulating the stability of their substrates (clients). Hsp90/heat
shock factor (HSF)1 pathway activation attenuates proteotoxicity. Meanwhile, activating the
Kelch-like ECH associated protein 1 (Keap1)/ nuclear factor (erythroid-derived 2)-like 2 (Nrf2)
pathway combats oxidative stress. Numerous studies attempted to individually manipulate the
expression of Hsp90 or Nrf2 to treat NDs.
Novel interactions of Hsp90 with Nrf2 and Keap1 were discovered via yeast-2-hybrid
screening (unpublished data). We analyzed their interactions through NMR spectroscopy, ITC,
protein-binding assay, Western blotting, and RT-qPCR. We demonstrated that Hsp90 and STIP1
are modulators of both Nrf2 and Keap1’s protein stability. Keap1 directly binds with STIP1 and
Hsp90. Keap1 interacts Hsp90 via the Kelch domain. Our study revealed potential crosstalk
between Keap1/Nrf2 and Hsp90/HSF1 cytoprotective pathways and the possibility of comodulating them.

Key Words: Neurodegenerative disease, Nrf2, Keap1, Hsp90, HSF1, STIP1, Molecular
chaperones, Co-chaperones, Clients, Oxidative Stress, Proteotoxic Stress, NMR spectroscopy
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Summary for Lay Audience
This work addresses the biophysical and biological analysis of Nrf2 and Keap1 as client
proteins of Hsp90 chaperone machinery, which can provide valuable insights into treatment
designs towards neurodegenerative diseases (ND). Heat shock protein (Hsp) 90, one of the most
abundant and evolutionary conserved molecular chaperones, modulates protein folding,
proteostasis maintenance, and proteotoxicity clearance. Substrate proteins that interact with
Hsp90 are called clients. The proper folding and functionality of Hsp90 clients are maintained
through the chaperone networks and co-chaperones, such as Stress-inducible protein 1 (STIP1).
This network and the clients of Hsp90 are found to play important roles in neurodegenerative
diseases. The inhibition of Hsp90 activates the heat shock factor (HSF)1- mediated heat shock
response (HSR), which attenuates the harmful aggregated protein Amyloid- (A) and taurelated toxicity in Alzheimer’s disease. Meanwhile, Nuclear Factor Erythroid 2-Related Factor
2 (Nrf2), a master regulator of antioxidative response, combats oxidative stress and the
proteotoxicity, such as the neuronal Aβ oligomer toxicity. Numerous studies are devoted to
separately manipulating the level of Hsp90 or Nrf2 in treating ND. Here we provide insights
into the crosstalk of the Nrf2- and Hsp90-mediated cytoprotective pathways implying the
potential in co-modulating their levels.
Novel interactions of Hsp90 with Nrf2 and Kelch-like ECH associated protein 1 (Keap1),
the negative regulator of Nrf2, were discovered via yeast-two-hybrid screening by our
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collaborator, Dr. Duennawald. Following this result, we analyzed their interactions through
NMR spectroscopy, ITC, protein-binding assay, Western blotting, and RT-qPCR. Our findings
showed that both Hsp90 and STIP1 interacts with Nrf2 and Keap1. Specifically, Keap1
interacted with Hsp90 via the Kelch domain. In addition, by using the genetically modified
mouse models recently developed by Dr. Prado’s lab, we investigated the functional
consequences of these interactions in vivo. Our data indicated that STIP1 plays a critical role
in Hsp90’s ability to modulate the protein stability of Keap1 and Nrf2. The interactions of
Hsp90 with Keap1 and Nrf2 reveal exciting underlying crosstalk in Keap1/Nrf2 and
Hsp90/HSF1 cytoprotective pathways and the potential in co-modulating these pathways.
Further characterizing their interacting mechanisms and cellular functions may provide
valuable insights in treating neurodegenerative diseases.
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CHAPTER 1: INTRODUCTION
1.1

Neurodegenerative Diseases
Neurodegenerative disease is an umbrella term encompassing disorders such as Alzheimer’s

disease (AD), Parkinson’s disease (PD), Huntington’s diseases (HD), Amyotrophic Lateral Sclerosis
(ALS) (Dinkova-Kostova & Kazantsev, 2017). Many of these diseases show pathological symptoms
such as problems with movements or deterioration in mental functioning, called dementia
(Neurodegenerative Disease Research, JPND). Dementia causes enormous burdens towards the
Canadian health care system with more than 419,000 Canadians diagnosed with such conditions in 2016,
and about 76,000 new cases per year (Canadian institutes of health research, CCNA). The fast-growing
prevalence of neurodegenerative diseases leads to socioeconomic impacts such as burden in private
household caregiving, government-provided long-term residential care facilities, and national financial
costs up to $22.7 billion annually (NeuroScience Canada 2006). Moreover, the world health
organization estimates that neurodegenerative diseases will become the second leading cause of death
in Canada by 2040 (NeuroScience Canada 2006).
Neurodegenerative disorders are diseases of the central nervous system that cause debilitating
effects to neurons. These disorders share neuropathological symptoms encompassing aberrant protein
disrupting protein-related homeostasis, oxidative stress, and free radical formation, the dysfunctionality
of mitochondria and neuroinflammatory responses (Jellinger, 2003; 2010). The sequence of these
1

pathological events is not determined, therefore, the cause of the neurodegenerative disorders remained
a mystery. Numerous efforts have been devoted to developing effective drugs for treating such harmful
cellular events (Dinkova-Kostova & Kazantsev, 2017; Neef et al., 2010; Patel & Mandal, 2018; Youdim
&

Buccafusco,

2005).

In

brief,

contemporary

therapeutic

approaches

towards

treating

neurodegenerative disease are separated into categories such as mitochondrial-direct therapies, stem
cell therapies, epigenetic modulator-related therapies, and mitochondrial dynamics modulator-related
therapies (Patel & Mandal, 2018). Yet the currently available treatments of neurodegenerative diseases
remain incapable of modifying the disease resulting in incomplete and transient benefits in treating
patients (Patel & Mandal, 2018).
Two major common pathological hallmarks found in neurodegenerative diseases are the excessive
amount of reactive oxygen species creating oxidative stress (OS) and impairments of protein
homeostasis (proteostasis), folding, trafficking and degradation (Dinkova-Kostova & Kazantsev, 2017;
Khanam et al., 2016; Neef et al., 2010; Pajares et al., 2017; Patel & Mandal, 2018). Targeting these
underlying factors represents a possibility in counteracting neurodegeneration. Two cytoprotective
pathways, Keap1/Nrf2 pathway and Hsp90/HSF1 pathway play essential roles in combating OS and
loss of proteostasis, respectively. The results of my study provide evidence of possible cross-talks
between these pathways, which could shed valuable insights into developing therapeutic drugs that
target them to treat neurodegenerative diseases.
2

1.2

Molecular Chaperone
Protein misfolding is one of the critical pathological factors in numerous neurodegenerative

diseases such as Parkinson’s, Huntington’s, ALS, Frontotemporal lobar degeneration (FTLD) and
Alzheimer’s Disease (Koh et al., 1990; Pike et al., 1992; Yanker et al., 1989). Misfolded proteins tend
to expose large hydrophobic surfaces leading to the formation of protein aggregates. These aggregates
could cause deleterious effects in cells due to their inability to maintain their native structure for proper
functionalities (Chiti & Dobson, 2006; Walsh & Selkoe, 2007).
Molecular chaperones are the major proteins that govern the proper folding of other proteins. The
term “molecular chaperone” was first used by Ron Laskey to describe nucleoplasmin, a protein that
binds and transport histones into the nuclear compartment (Laskey et al., 1978). Molecular chaperones
are considered as proteins that assist the folding, stabilizing, translocating, or degrading of other
proteins. Many proteins require the aids of the cellular chaperone machinery to fold into the functional
three-dimensional conformation (Hartl & Hayer-Hartl, 2009). For instance, essential proteins such as
actins and tubulins have low intrinsic folding efficiencies and cannot fold without chaperones (Hartl
& Hayer-Hartl, 2009). Chaperones also play critical roles in activities that maintain proteostasis such
as stabilizing non-native proteins, refolding of stress-denatured protein, oligomeric assembly,
intracellular protein transport, and proteolytic degradation (Hartl & Hayer-Hartl, 2009). Many
chaperones are stress protein or heat-shock protein (Hsp) that are upregulated during proteolytic stress
3

caused by an increased amount of aggregating unfolded proteins. They are often named after their
molecular weight, for instance, Hsp40, Hsp60, Hsp70, and Hsp90. Together they form complex
intracellular chaperone networks (Balch, 2008). Chaperones, such as Hsp70 and Hsp90, mainly bind
exposed hydrophobic amino acid sidechains on misfolded proteins, thus inhibit their aggregation
tendency and promote the refolding process via ATP-regulated cycles (Balch, 2008; Hartl & HayerHartl, 2009).
Neurodegenerative disorders such as Alzheimer’s, Parkinson’s, Huntington’s and prion diseases
share pathological states in which deposition of fibrillar aggregates and aberrantly folded proteins
cause neuronal cytotoxicity (Chiti & Dobson, 2017; Muchowski et al., 2000; Reis et al., 2017). Recent
advances in understanding the aging process indicate that protein quality declines as the functional
capacity of chaperones decreases (Balch, 2008; Sittler et al., 2001). Studies using cell culture, fruit fly,
and mouse models showed enhancing the protein-folding ability of cells through elevating chaperone
protein expression provides positive benefits in modifying the neurodisorder pathology caused by
misfolded protein (Neef et al., 2012). Therefore, further investigation of the cellular chaperone
machinery network and their roles in helping protein fold is of utmost importance.
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1.3

Heat Shock Protein (Hsp) 90

1.3.1 Hsp90 Chaperone Mechanism
Hsp90 is conserved in bacteria and all eukaryotes, indicating its importance to a large number
of organisms and the long history in evolution (Dinkova-Kostova & Kazantsev, 2017; Genest et al.,
2019: Radii et al., 2017; Prodromou, 2017). Hsp90 protein found in Escherichia coli is called HtpG
(Li & Buchner, 2012). In yeast, two isoforms of Hsp90 existed in the cytosol, Hsc82, and Hsp82 (Li
& Buchner, 2012). In mammalian cells., two major isoforms of Hsp90, Hsp90α (inducible and major
form) and Hsp90β (constitutive and minor form) exist in the cytoplasm (Li & Buchner, 2012). In
particular, Hsp90β was required for early embryonic development and long-term cellular adaptation
(Li & Buchner, 2012; Sreedhar et al., 2004).
Hsp90 interacts with a large (> 2000) and diverse pool of substrate proteins (which are often
referred to as clients) that perform essential cellular functions, such as signaling proteins (i.e., HSF1),
kinases (i.e., cyclin-dependent kinase), steroid hormone receptors (i.e., glucocorticoid receptor) and
disease-related proteins (i.e., tumor suppressor p53, the microtubule-binding protein Tau) (Pearl &
Prodromous, 2016; Taipale et al., 2010). Among these clients, many of them are oncogenic proteins
that are crucial for cancer progression, making Hsp90 a therapeutic target for cancer treatments
(Genest et al., 2019). Moreover, the Hsp90 also modulates the quality of essential proteins and the
5

degradation of aberrant proteins that tend to aggregate in neurodegenerative diseases, making it a
possible target in treating neurological disorders. Interestingly, the client proteins of Hsp90 vary in
structure as well as sequence, implying that the specificity of Hsp90 in interacting with its clients
remains to be understood.
Hsp90 also forms machinery with Hsp70/Hsp40 chaperones to support protein folding,
oligomeric assembly, damaged protein repair, and degradation (Kim et al., 2013; Saibil, 2012;
Winkler et al., 2012). This system involves the cochaperone STIP1 that allows clients to be
transferred from Hsp70 to Hsp90 during the protein folding process (Pratt et al., 2015). Specifically,
STIP1 interacts with both Hsp70 and Hsp90 to stabilize their interactions with clients (Sung et al.,
2016). Many studies sought better understandings towards the client - chaperone interactions and
their involvement in biological processes for their essential roles in cellular survival and
neurodisorder-related treatments. Therefore, the manipulation of Hsp70/Hsp90 machinery in studies
not only facilitates the understanding of their clients but also help validates similar experimental
methods and the litany of studies which it depends on (Alvira S et al., 2014; Genest et al., 2019;
Kirschke et al., 2014; Verba et al., 2016).
At the native cytosolic state, Hsp90 exists as a homodimer. The protein is composed of three
domains: The N-terminal domain (NTD), the middle domain (MD), and the C-terminal domain
(CTD). Both the NTD and MD of Hsp90 participate in ATP-hydrolysis, whereas the CTD is
6

responsible for the dimerization. The MD is also involved in interacting with Hsp70, whereas the
MEEVD motif in CTD mediates the binding with many co-chaperones containing tetratricopeptide
repeat (TPR) domains, including STIP1 (Florian et al., 2017; Lackie et al., 2017; Zuehlke et al., 2017).
Besides, the long, flexible, and the charged linker between NTD and MD has also been shown to
modulate the conformation and co-chaperone interaction of Hsp90 (Hainzl, 2009; Jahn, 2014; 2018;
Tsutsumi, 2009; 2012).
All three domains of Hsp90 are involved in recruiting different sets of clients. In addition, the
ATP hydrolysis function of Hsp90 plays an essential role in the binding and release of some of its
clients. Hsp90 is highly dynamic in structure. It cycles through different conformation states, such as
apo state, ATP-bound state, and the ADP-bound state, during the ATP hydrolysis process (Krukenberg
et al., 2008; Southworth & Agard, 2008). Hsp90 ATP chaperone conformational cycle starts with the
open apo conformation. The binding of ATP to the NTD of Hsp90 causes the protein to change into
a closed conformation where the NTD and MD promote the ATP hydrolysis. When the ATP is
hydrolyzed, Hsp90 releases the ADP product and returns to the apo-state (Ali et al., 2006; Lavery,
2014; Shiau et al., 2006; Tsutsumi, 2009). The ATP hydrolysis mechanism is conserved among
eukaryotic Hsp90 species implying the importance of ATP hydrolysis in Hsp90’s in vivo functions
(Richter et al., 2008).
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1.3.2 Hsp90/HSF1 - Mediated Heat Shock Response
Heat Shock Factor 1 (HSF1), a client of Hsp90, is a master regulator of heat shock response
(HSR) (Akerfelt et al., 2010; Neef et al., 2012). HSF1 belongs to the vertebrate family of HSF
proteins and is conserved in its protein structure across yeast, fruit fly, and mammalian cells (Akerfelt
et al., 2010). It mediates the transcriptional activation of the HSR, which can be triggered by
cytoplasmic proteotoxic stimuli, including increased temperature, oxidative stress, bacterial and viral
infection (Lackie RE et al., 2017; Neef et al., 2012). The activation of HSR primarily promotes the
expression of genes encoding multiple chaperones to combat cellular stress and other essential
cellular events, including protein degradation, ion transportation, signal transduction, energy
generation, carbohydrate metabolism and cytoskeleton formation (Akerfelt et al., 2010; Gonsalves et
al., 2011; Hahn et al., 2004; Trinklein et al., 2004).
The regulation of HSF is stress-dependent and controlled through multiple chaperones and cochaperone regulatory mechanisms (Neef et al., 2012) (Figure 1). Under basal homeostasis conditions,
HSF1 is repressed through the activity of chaperone proteins, including Hsp90, Hsp70, Hsp40 and
other co-chaperones (Ali et al., 1998; Bharadwaj et al., 1999; Guo et al., 2001; Neef et al., 2012).
The role of Hsp70 and Hsp40 focuses on binding to the transcriptional activation domain of HSF1 to
repress its activation (Neef et al., 2012). Meanwhile, Hsp90 and co-chaperone 23 with other proteins
together bind with the regulatory domain of HSF1 (Ali et al., 1998; Bharadwaj et al., 1999; Guo et
8

al., 2001; Neef et al., 2012).
When entering cellular proteotoxic-related stress, HSF1 gets released from the protein complex
formed by the multiple chaperones and co-chaperones previously mentioned (Lackie et al., 2017;
Neef et al., 2012). This allows HSF1 to translocate into the nucleus (Lackie et al., 2017). After
translocation into the nucleus, HSF1 homotrimerizes and binds to the cis-acting heat shock elements
in the stress responding genes to upregulate the expression of many essential chaperones and cochaperones, such as Hsp90, Hsp70, Hsp27 and Hsp40 (Neef et al., 2012). The upregulation of such
cytoprotective proteins can support protein integrity and disposal (Lackie et al., 2017). The
phosphorylation of HSF1 at specific serine residues further promotes its transcriptional activity.
However, the mechanism of phosphorylation events remains undetermined (Neef et al., 2010).
Moreover, the fate of HSF1 after dissociation from DNA also remains to be determined (Yang et al.,
2008). Knock-down of HSF1 expression has been shown to enhance the neuropathological effects of
toxic misfolded proteins, implying the potential of upregulating HSR in treating ND (Karam et al.,
2017; Kraemer et al., 2006; Nollen et al., 2004; Wang et al., 2009).

9

Figure

1

Figure 1. Model of the Hsp90-HSF1 Heat Shock Response Pathway. HSF1 is believed to reside
in a complex with Hsp90, Hsp70, and Hsp40 in the cytosol. When the cell is under proteotoxic stress
or heat stress, the unfolded or misfolded proteins competed with HSF1 to bind with Hsp90
chaperones and co-chaperones. The unbound HSF1 monomers trimerize as they translocate into the
nucleus, which leads to the upregulation of more chaperones and co-chaperones to combat against
proteotoxic stress.
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1.4

Co-chaperone Stress-Inducible Phosphoprotein 1 (STIP1)
Hop/STI1/STIP1 is a co-chaperone of the Hsp70/Hsp90 machinery (Röhl et al., 2015; Scheufler

et al., 2000). It resides in the cytosol but can also shuttle between the nucleus and cytoplasm
(Longshaw et al., 2004). STIP1 consists of three TPR domains (TPR1, TPR2A, and TPR2B) and two
domains rich in aspartate and proline residues (DP1 and DP2). During the chaperone-assisted client
folding, Hsp70 first interacts with the TPR1 and TPR2B domains of STIP1 (Pratt et al., 2015). Hsp90
then binds to the TPR2A domain, which interferes with the interaction between Hsp70 and the TPR2B
domain (Pratt et al., 2015). The binding of Hsp90 and STIP1 reorganizes the ternary Hsp70-clientSTIP1 complex, allowing the client to be transferred to Hsp90 (Pratt et al., 2015). The role of the DP
domains of STIP1 remains unclear currently (Pratt et al., 2015). In addition, TPR2A-TPR2B-DP2 is
the minimal fragment of STIP1 that is required for the client transfer implying the essential
functionalities of these domains (Pratt et al., 2015; Schmid et al., 2012).
The deletion of the TPR1 domain hampers the client transfer from Hsp70 to Hsp90, which leads
to a decline in the client protein level (Karam et al., 2017). The deletion of STIP1 leads to decreases
of various Hsp90 client’s protein levels, implying its vital role in maintaining cellular proteostasis
(Beraldo et al., 2013; Lackie et al., in preparation; Longshaw, 2004; Nollen et al., 2004). The deletion
of STIP1 in mice is shown to be lethal, indicating its essential cellular functions towards organism
survival (Beraldo et al., 2013).
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1.4.1 The study of modulation of client stability by Hsp70/Hsp90/STIP1
chaperone machinery
As previously mentioned, the folding of client proteins starts with forming a complex with
Hsp70 and its co-chaperone Hsp40 and then gets transferred to Hsp90 through the assistance of cochaperone STIP1 (Lackie et al., in preparation). This chaperone machinery plays a crucial role in
protein quality control, which is important to neurodegenerative disorder studies (Fontaine et al.,
2016; Lackie et al., in preparation). However, the role of STIP1 and Hsp70/Hsp90 in maintaining
proteostasis in mammals is not well understood. Dr. Marco Prado’s lab addressed this question
through generating a mouse line with STIP1 hypomorphic allele in mice to observe the effects of
reducing STIP1 gene expression on the client proteins as well as the survival of these mice. Moreover,
a CRISPR–Cas9 STIP1 knockout neuronal cell line was developed as well to further investigate the
importance of STIP1 in the functionality of Hsp70/Hsp90 chaperone machinery (Lackie et al., in
preparation). These studies revealed the importance of STIP1 in maintaining the neuronal resilience
during aging and the functionality of the chaperone network, especially in neurodegeneration
conditions (Lackie et al., in preparation).
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1.4.1.1 Homozygous mutant STIP1 mice (△TPR1 mice)
The hypomorphic TPR1-deprived STIP1 mice were generated by removing the exons 2 and 3
of the STIP1 gene using the Cre/lox system (Lackie et al., in preparation). These homozygous mutant
STIP1 mice (△TPR1 mice) are an excellent tool in understanding the importance of the TPR1 domain
of STIP1 in assisting the client transfer between Hsp70 and Hsp90.
The △TPR1 mice were found to be viable but had a significantly lower birth rate than Mendelian
distribution (Lackie et al., in preparation). Lackie’s results showed that the △TPR1 mice had a high
mortality rate during an early age, which suggested that the reduction of STIP1 protein level caused
by deleting the TPR1 domain caused an increased mortality rate. This indicated that STIP1 plays an
essential role in mammalian development. More interestingly, many proteins that were involved in
Hsp70/Hsp90 network functionality and protein folding presented a decrease in the protein
expression but without a significant change in gene expression. For example, a peptidyl-prolyl
cis/trans isomerase (PPIase) called Pin1, which coordinates with the Hsp90 chaperone complex and
regulates the phosphorylation of tau protein, showed 50% reduction in protein expression (Dickey et
al., 2007; Lackie et al., in preparation). The reduction of these protein levels in △TPR1 mice indicates
that the TPR1 domain of STIP1 is vital for maintaining the proteostasis and it plays a crucial role in
STIP1’s ability to regulate the stability of Hsp90 and co-chaperones involved in Hsp70/Hsp90
chaperone machinery (Lackie et al., in preparation).
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Many client proteins of the Hsp70/Hsp90 chaperone machinery also showed a reduction in
protein levels in the △TPR1 mice (Lackie et al., in preparation). Specifically, glucocorticoid receptor
(Gr), Tau protein, and G protein-coupled receptor kinase 2 (GRK2), which are all Hsp90 client
proteins, all showed a significant reduction in protein expression but without gene-level changes
(Lackie et al., in preparation). These results showed that the client proteins of Hsp90 could largely
depend on the functionality of the TPR1 domain of STIP1 to become fully folded or stable.

1.4.1.2 SN56 – STIP1 KO Cell Line
The SN56 – STIP1 Knockout cell line (SN56-STIP1 KO) was developed by using optimized
CRISPR Design (http://crispr.mit.edu/) to design the guide RNAs for the Stip1 gene. The construct
was sequenced and used to transfect SN56 cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA). The resultant clones that showed complete elimination of STIP1 protein expression were used
to investigate further the importance of STIP1 in regulating Hsp90 client protein and co-chaperone
as well as protecting neuronal cells from environment stress (Lackie et al., in preparation).
The SN56 -STIP1 KO cells showed an increase in the cell death levels compared to the SN56
wild-type (WT) cells (Razzaq, 2018; Lackie lead, in preparation). This indicated that STIP1 was
crucial for the survival of neurons, and deleting STIP1 compromises the neuron’s ability to combat
environmental stresses. Moreover, co-chaperones and client proteins of Hsp90, such as FK506
binding protein 51 kDa (FKBP51), CypA, Pin1, Glucocorticoid Receptors, all showed a reduction in
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protein expression level (Razzaq et al., 2018). The decrease of client protein levels indicated that a
loss of proteostasis is related to the loss of STIP1 in neurons. These results together suggest that
STIP1 is a critical co-chaperone that regulates the Hsp70/Hsp90 machinery and is required for the
recruitment and stabilization of Hsp90 client proteins (Beraldo et al., 2013; Lackie et al., in
preparation).
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1.5

Keap1/Nrf2-Mediated Oxidative Stress Response

1.5.1 Nrf2 as a Transcription Factor in the pathway
Reactive oxygen species (ROS) are oxygen metabolism by-products that play essential roles in
cell signaling (Deshmukh et al., 2017). The excessive accumulation of oxidative stress (OS) and ROS
production can disrupt the cellular antioxidative mechanism. Distrupting the redox homeostasis leads
to proteostasis imbalance, DNA modification, inflammations (Browne & Beal, 2006; Johnson &
Johnson, 2015; Kerr et al., 2017). These harmful effects contribute to the progression of many
neurodegenerative diseases (Browne & Beal, 2006; Johnson & Johnson, 2015; Kerr et al., 2017).
Also, common pathological features such as aggregating aberrant proteins, microglial activation, and
mitochondrial dysfunction could generate more ROS and OS that cause more damages to the central
nervous system (Deshmukh et al., 2016). The critical pathway that combat the OS/ROS damages and
degradation of misfolded aggregated proteins is mediated by transcription factor; nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) (Pajares et al., 2017).
Nrf2 is considered as a master regulator of cellular redox homeostasis and removal of damaged
proteins under OS/ROS conditions (Johnson & Johnson, 2015; Kerr, 2017; Pajares M. et al., 2017).
It belongs to the Cap ‘n’ Collar (CNC) family of the basic leucine zipper regulatory proteins
(Deshmukh et al., 2017). The CNC family proteins contain CNC domains that heterodimerize with
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small Maf proteins to bind with DNA to regulate gene expressions (Derjuga et al., 2004; Deshmukh
et al., 2017). This protein family also includes other transcription factors such as NF-E2, Nrf1, Nrf3,
Bach1, and Bach2 (Motohashi et al., 2002). Amongst these proteins, Nrf2 is the most intensively
studied due to its essential function in cellular redox metabolism (Chan et al., 1993). Human Nrf2
has 605 amino acids and is composed of seven well-conserved functional domains, Nrf2-ECH
homology (Neh) 1-7 (Baird L & Dinkova-Kostova, 2011; Wang et al., 2013). Each domain plays an
essential role in the function of Nrf2, but herein, the relevant domains would be briefly introduced.
The Neh1 domain is involved in CNC and DNA binding, which dimerizes with Maf small protein
(Deshmukh et al., 2017; Johnson & Johnson, 2015). The Neh2 domain, containing lysine residues
that can be ubiquitinated by CUL3-dependent E3-ubiquitin ligases, is required for the negative
regulation of Nrf2 (Johnson & Johnson, 2015; Sekhar et al., 2002). The Neh3 domain plays an
essential role in promoting the transcription of cytoprotective genes (Nioi et al., 2005).
Nrf2 mediates the basal and stress-inducible expression of cytoprotective antioxidative genes
participating

in

the

phase

I,

II

and

III

detoxifying

metabolism,

glutathione

and

peroxiredoxin/thioredoxin metabolism and NADPH production, i.e., the detoxifying and oxidative
stress enzyme, xenobiotic-metabolizing, and other cytoprotective genes (Kobayashi et al., 2006; Itoh,
1999; Pajares et al., 2017; Zhang et al., 2013). Nrf2 induces these cytoprotective genes expression
by targeting the antioxidative responsive element (ARE). ARE (which is called electrophile response
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elements (EpREs)) is a cis-regulatory element found in the upstream promoter regions of many phase
II metabolic genes (Rushmore et al., 1990; 1991). The phase II metabolic genes encode enzymes,
such as glutathione-transferase (GST), quinone oxidoreductase 1 (NQO1) and NAD(P)H, that are
critical in detoxifying xenobiotics and combating oxidative stress in response to electrophiles and
oxidants (Zhang et al., 2013). The cytoprotective importance of Nrf2 has been shown through the
phenotype of the Nrf2 null mice which experiences higher sensitivity towards xenobiotics such as
benzo(a)pyrene, butylated hydroxytoluene, acetaminophen, and etc (Aoki et al. 2001; Calkins et
al. 2005; Chan & Kan, 1999; Enomoto et al. 2001; Khor et al. 2006; 2008; Xu et al. 2006).
The Nrf2-mediated antioxidative pathway plays a preventative and cytoprotective role in
combating oxidative stress (Kobayashi et al., 2006; Itoh, 1999; Pajares et al., 2017; Zhang et al.,
2013). Targeting the activation of Nrf2 for upregulating various enzymes has been the center of
research themes, including detoxifying carcinogens, chemotherapeutic and radiotherapies (Kensler
& Wakabayashi, 2010; Lau et al., 2008; Takahashi et al., 2015). Recent studies showed that the
expression of phase II enzymes also provided neuroprotection to the central nervous system
(Deshmukh et al., 2016; Zhang et al., 2013). This is because the pathophysiological events found in
neurodegenerative diseases often cause the accumulation of OS and ROS, leading to damages to
lipids, proteins, and DNA (Deshmukh et al., 2016). Therefore, it is crucial to study the role of the
Nrf2-mediated pathway in order to provide helpful guidance to therapeutic development for treating
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neurological disorders.

1.5.2 Keap1 as the Major Negative Regulator of Nrf2
Kelch-like ECH associated protein 1 (Keap1) is a major negative regulator of the Keap1/Nrf2
pathway (Zhang et al., 2013). It functions as a substrate adaptor of a CUL3-dependent E3-ubiquitin
ligase complex that targets Nrf2 for ubiquitination-dependent degradation (Bryan et al., 2013;
McMahon et al., 2004; Ogura et al., 2010). The 624-amino acid human Keap1 consists of four
domains: The Broad complex Tramtrack and Bric-a-Brac (BTB) domain, the intervening region
(IVR), the double glycine repeat (DGR) and the C-terminal region (CTR) (Ogura et al., 2010). The
Keap1 is found to be highly conserved among eukaryotes such as mice and humans (Deshmukh et
al., 2017; Li et al., 2007). Keap1 exists as a homodimer primarily in the cytoplasm that also shuttles
to the nucleus (Sun et al., 2011; Zhang et al., 2013). The BTB domain plays the role of dimerizing
Keap1 as well as stress sensing through the cysteines in its structure (Deshmukh et al., 2017; Ogura
et al., 2010). The IVR domain is crucial for sensing electrophilic and oxidative stress due to the two
critical cysteine residues, Cys273, and Cys288 (Deshmukh et al., 2017; Ogura et al., 2010). Moreover,
the BTB domain and the IVR domain together are important for the polyubiquitination and 26S
proteasomal mediated degradation for Nrf2 (Deshmukh et al., 2017). The functions of DGR and CTR
regions, which is called Kelch domain together, are mainly focusing on repressing Nrf2 activity
(Canning et al., 2015; Deshmukh et al., 2017; Ogura et al., 2010).
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The binding of Keap1 to Nrf2 triggers the clearance of excessively produced Nrf2 through
CUL3-dependent E3-ubiquitin ligase-mediated ubiquitination (Kobayashi et al., 2004). Under the
basal homeostatic condition, Keap1 binds Nrf2 through the Kelch domain to send it for degradation
by the proteasome (Ogura et al., 2010). The Kelch domain of Keap1 contains six Kelch repeats that
form a six-bladed β-propeller structure (Canning et al., 2015). This β-propeller structure form
electrostatic interactions with the Neh2 domain of Nrf2 through two sites: the weak affinity binding
site called the DLG motif (residues 24-31); and the strong affinity binding site called the ETGE motif
(residues 78 – 82) (Zhang et al., 2013). This combination forms a strong and weak affinity “hingeand-latch” model that inhibits the activation of Nrf2 in the cytosol (Canning et al., 2015; Zhang et
al., 2013). Previous studies have shown that the DLG binds to Kelch 100-fold weaker compared to
the affinity of ETGE binding to Kelch (Tong et al., 2006).
Electrophilic/oxidative stress leads to structural modifications of the Keap1 homodimer
(Deshmukh et al., 2016). Notably, Keap1 is structurally abundant in cysteine residues, with 25
cysteines found in mouse and 27 cysteines in human homologs (Johnson & Johnson, 2017). Previous
studies revealed that amongst all the cysteines that existed in Keap1, Cys273, and Cys288 are the
two most crucial ones in causing the conformational changes of Keap1 (Deshmukh et al., 2016; Ogura
et al., 2010). Under stress conditions, these cysteine residues are covalently modified, causing the
structural changes of Keap1. This leads to the dissociation of Keap1 from the DLG motif of Nrf2
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(Taguchi et al., 2011). The high levels of newly synthesized Nrf2 proteins quickly accumulate and
translocate into the nucleus. Eventually, Nrf2 binds to the ARE and promotes the expression of a
large group of cytoprotective genes that are responsible for combating detoxifications, antioxidant,
and proteostasis restoring genes (Figure 2) (Baird et al., 2014; Furukawa et al., 2005; Joshi et al.,
2015; Khan et al., 2015; Kang et al., 2004; Kobayashi et al., 2004; Zipper et al., 2002).
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Figure

2

Figure 2. Model of the Keap1-Nrf2 Antioxidative Response Pathway. At basal state, Keap1
represses Nrf2 by promoting its degradation. And under oxidative stress, Nrf2 disassociates from
Keap1 and activates the transcription of antioxidative elements.
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1.5.3 Keap1 / Nrf2 - Mediated Pathway & Neurodegenerative Diseases
The Keap1/Nrf2 pathway plays an essential role in protecting against many neurological diseases
(Zhang et al., 2013). In the following content, various neurodegenerative diseases and the importance
of the Keap1/Nrf2 pathway towards treating these disorders would be discussed.
Parkinson’s disease is characterized by the loss of dopaminergic neurons and the deposition of
Lewy bodies in many regions of the brain (Tufekci et al., 2011). Previous studies have shown that
Nrf2 exists with higher expression in PD patients, which may be due to neurons’ attempt to combat
oxidative toxicity (Ramsey et al., 2007).
Alzheimer’s disease is a neurodegenerative disease associated with loss of neurons, the formation
of intracellular neurofibrillary tangles and the deposition of amyloid-beta (Ramsey et al., 2007).
Researchers have found that Nrf2 expression is extremely low in AD patients. The decline of
Keap1/Nrf2 related proteins are associated with a significant amount of amyloid-beta deposition, and
over-expressing Nrf2 through Nrf2-activator could provide neuroprotection against AD pathological
symptoms (Kanninen et al., 2008; Ramsey et al., 2007).
Multiple sclerosis (MS) is an autoimmune and inflammatory disease that is believed to be
initiated by the toxicity caused by abnormal activation of CD4+ T cells which led them to cross the
blood-brain barrier inappropriately (Benedict & Zivadinov, 2011). Increasing evidence has shown that
Nrf2 is essential for the proper functioning of CD4+ T cells. For instance, Nrf2 knockout mice showed
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increased expression of inflammatory enzymes and enhanced immune cell (CD4+ T cells) activation
(Johnson et al., 2010). Moreover, promoting the Nrf2 activation via modifying Keap1 structure or
inducing Nrf2 expression have been shown to suppress neuroinflammation, which is beneficial in
treating MS (Linker et al., 2011; Pareek et al., 2011).
Huntington’s Disease (HD) is an autosomal dominantly inherited neurodegenerative disease
caused by the genetic condition that leads to abnormal body movements, cognitive impairments, and
personality changes (Kumar et al., 2010). Evidence suggested that elevation of Nrf2 expression can
reduce the pathological symptoms in HDs such as striatal atrophy, mitochondrial impairment and the
neuron lesions (Calkins et al., 2005; Stack et al., 2010). ALS is a neurodegenerative disease caused by
loss and degeneration of neurons among the spinal cord, brain stem, and motor cortex. The elevated
level of Nrf2 triggered by Nrf2-inducers significantly reduces the progression of ALS in mouse models
and protects motor neurons against toxicity caused by mutated proteins found in ALS (Pehar et al.,
2007; Neymotin et al., 2011).
In conclusion, the Keap1/Nrf2-mediated cytoprotective pathway is significant in protecting
neurons from various neurodegenerative diseases as well as in treating neurological diseases
previously mentioned (Zhang et al., 2013).
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1.6

Crosstalk Between the Keap1/Nrf2 and Hsp90/HSF1 Cytoprotective
Pathways
Both Keap1/Nrf2 and Hsp90/HSF1 cytoprotective pathways that play crucial roles in neuronal

survival and neuroprotection against oxidative and proteotoxic stress. Multiple previous studies
indicated connections between these two pathways, which were previously believed to be
independent of each other. However, the molecular mechanism of their connection remained unclear.
For example, Satoh et al. (2011) found that both pathways can be activated by the same proelectrophilic toxic to provide neuroprotection against oxidative stress and endoplasmic reticulum
stress (Dinkova-Kostova & Kazantsev, 2017). Zhang et al. (2014) found that an inhibitor of Hsp90,
electrophilic sulphoxythiocarbamate, can also inhibit Keap1, leading to the activation of both
Keap1/Nrf2 and Hsp90/HSF1 pathways. Naidu et al. (2015) demonstrated that Keap1/Nrf2 and
Hsp90/HSF1 pathways crosstalk by sharing transcription targets such as Hsp70, heme oxygenase 1,
p62, activating transcription factor 3, and they compensate each other when either one of the
pathways is compromised (Naidu et al., 2015). Miller and Ramos (2005) identified that Nrf2 and
Hsp90β (a constitutively expressed homolog of Hsp90) are components of the heterocomplex that
interacts with ARE/EpREs, which implied that Hsp90β might interact with Nrf2. These studies
illustrate the possibility of co-modulating both pathways to develop effective therapeutic drugs.
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1.7

The Scope of the Thesis
Typical pathological hallmarks, such as oxidative stress and proteotoxicity, found in NDs, are

closely related to the Hsp90/HSF1 and Keap1/Nrf2 cytoprotective pathways. Interestingly, our
collaborator, Dr. Martin Duennwald (Western University) has recently identified the interactions of
Hsp90 with Nrf2 and Keap1 via yeast-two-hybrid screening (unpublished data). The interactions
between these proteins may imply the crosstalk between the Keap1/Nrf2 and Hsp90/HSF1 pathways.
However, the molecular mechanisms of these interactions are unclear.
Following these findings, we investigated the molecular basis and functionality of the
interactions of Hsp90 with Keap1 and Nrf2. Our study revealed the underlying crosstalk between the
Keap1/Nrf2 and Hsp90/HSF1 cytoprotective pathways and the potential in co-modulating them.
Further characterizing their interacting mechanisms and cellular functions will provide valuable
insights in treating NDs.

HYPOTHESIS: We hypothesize that Keap1 and Nrf2 are clients of Hsp90, and Hsp90 together
with STIP1 modulates their protein stability.

We aim to understand the role of Hsp90 in mediating the Keap1-Nrf2 pathway through both in
vitro and in vivo approaches. In vitro studies include using protein-ligand binding assay (a
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modification of ELISA assay), isothermal titration calorimetry, and nuclear magnetic resonance
spectroscopy to characterize the interactions of Hsp90 with Keap1, STIP1 with Keap1, and the
interactions of Hsp90 with Nrf2.
In vivo studies utilize STIP1ΔTPR1 mouse line and SN56 wild type (WT) /SN56-STIP1-KO cell
line to study the gene and protein expression of Keap1 and Nrf2 as clients to STIP1/Hsp90 machinery
using Real-time quantitative Polymerase Chain Reaction (RT - qPCR), Western Blotting.
Our objectives include:
I.

Identify the interactions of Human Hsp90 with Keap1 and Nrf2 in vitro

II.

Determine whether Keap1 and Nrf2 are clients of Hsp90 in vivo

III.

Determine whether the interactions of Keap1 and Nrf2 with Hsp90 modulate their protein
stability in vivo
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CHAPTER 2: MATERIALS&METHODS
2.1 Protein overexpression and purification
2.1.1 Preparation of recombinant Kelch domain of human Keap1
2.1.1.1 Overexpression of recombinant Kelch domain of human Keap1
The expression and purification of recombinant Kelch domain of Keap1 were reported previously
(Khan et al. 2013). A brief description of the process of overexpressing and purifying Kelch will be
provided. The pET15b plasmid carrying the Kelch cDNA was introduced into Escherichia coli (E. coli)
BL21 (DE3) cells (Novagen) by the standard method (Sambrook & Russell, 2006). Bacteria were plated
onto Luria-Bertani (LB) agar media containing 50 µg/mL Carbenicillin (US biological) and were
incubated overnight at 37 ℃. A single colony was inoculated 2 mL of LB media with 50 µg/mL
Carbenicillin overnight at 37 ℃. After overnight growth, the bacteria culture was collected and stored
away with 300 µL/mL glycerol at -80 ℃.
When overexpressing Kelch, 20 µL of the media containing pET15b Kelch plasmid was taken out
of the stock and resuspended in 2 mL of LB media containing 50 µg/mL Carbenicillin as a starter culture.
The starter culture was incubated at 37 ℃ overnight. Then the 2 mL culture was directly added to 200
mL LB media with 50 µg/mL Carbenicillin per 1 L LB growth of bacteria. The 200 mL LB was grown
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overnight at 37 ℃. After the overnight growth, the bacterial cells were pelleted by centrifugation (6,
000 xg, 15 mins, room temperature, Avanti rotor JLA-16, 250) and were resuspended into 1 L of LB
media containing 50 µg/mL Carbenicillin to reach a starting OD600 of 0.09-0.12. The cell culture was
incubated at 37 ℃ until the OD600 reach 0.8-0.9. The Kelch overexpression was induced overnight with
1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG, BioShop) at 15 ℃. The cells were later harvested
after 18 hrs of growth with OD600 > 2.0. The bacterial cells were pelleted by centrifugation at 6,000 xg
for 20 mins in a Beckman JLA-9.1000 rotor. The pellets were washed with 1 x Dulbecco’s Phosphate
Buffered Saline, then with lipopolysaccharide (LPS) solution 1 (5 mM CaCl 2, 20 mM
Trisaminomethane/Tris

buffer

pH8.0)

and

finally

with

LPS

solution

2

(10

mM

Ethylenediamineteraacetic/EDTA acid, 20 mM Tris buffer pH 8.0). The pellet was collected by
centrifugation at 6, 000 xg for 20 mins in a Beckman JA 30.50 rotor, then stored at -20 ℃ until needed.

2.1.1.2 Purification of recombinant Kelch domain of human Keap1
Bacterial cells were thawed in 37 ℃ water bath and resuspended in 20 mL/g of Lysis buffer (20
mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, pH 8.0 – 9.0). The suspension was mixed with 2 scoops
of human lysozyme and incubated in 37 ℃ water bath for up to 30 mins. The suspension was then
subjected to lysis by Avastin Homogenizer. The product after lysis was mixed with protease inhibitor,
100 µL phenylmethylsulfonyl fluoride (PMSF) per 10 mL of suspension and was adjusted with
imidazole stock (1 M) as well as NaCl stock (5 M) to binding buffer (20 mM Tris-HCl, 500 mM NaCl,
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10 mM Imidazole, 1 mM EDTA, pH 7.8) concentrations. Cellular debris and protein precipitation were
removed by centrifugation at 40, 000 xg in JA 30.5 rotor at 4 ℃ for 30 mins. The resulting supernatant
was adjusted to 7.8 pH using 1 N HCl stock and was then combined with 10 mL of binding buffer
equilibrated Ni-Sepharose beads and incubated at room temperature (22 ℃) for about 2 hrs. The Nisepharose beads were poured back into a 50 mL column and washed by gravity using 100 mL of binding
buffer (20 mM Tris-HCl, 1 mM EDTA, 10 mM Imidazole and 500 mM NaCl at pH 7.8) followed by
500 mL wash buffer A (20 mM Tris-HCl, 500 mM NaCl, 20 mM Imidazole at pH 7.8) and 500 mL
wash buffer B (20 mM Tris-HCl, 500 mM NaCl, 40 mM Imidazole at pH 7.8). The bound Kelch was
eluted over a 30 mins duration with 5 mL fractions by gravity flow with elution buffer (20 mM TrisHCl, 500 mM NaCl, 750 mM Imidazole at pH 7.8). Protein containing fractions were determined by
qualitative BioRad assay and pooled together. The eluted protein solution was desalted through being
dialyzed in 2 L dialysis buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid/Hepes, 100
mM NaCl, 1 mM Dithiothreitol/DTT at pH 7.5) using a Spectra/Por 6 dialysis tubing with a molecular
weight cut-off (MWCO) of 30 kDa overnight and then another 4 hrs.
The dialyzed protein sample was centrifugated to remove precipitation (40, 000 xg, 15 mins, at 4 ℃).
Then the protein sample was filtered through a 0.20 µm low protein binding membrane filter (Pall)
before further purification process. Every 20 mg of the Kelch protein was combined with 10 µL of 21.2
U/µL thrombin stock and was incubated overnight at 4 ℃. The next day, the cleaved Kelch protein
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sample was loaded to the dialysis buffer equilibrated HiLoad S75 Column and was eluted with 1 mL
fractions. The collected fractions were analyzed by sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) using 12 % gels with Coomassie Brilliant Blue R-250 staining. Fractions
that contained the pure Kelch protein were pooled and subjected to a BioRad assay to determine the
protein concentration. The final pure Kelch sample was used for further experiments.

2.1.2 Preparation of recombinant Human Keap1
2.1.2.1 Overexpression of recombinant Human Keap1
The pET1b plasmid carrying the Keap1 cDNA was introduced into Rosetta 2 (DE3) pLysS cells
(Novagen) by the standard method (Sambrook & Russell, 2006). The Bacteria were stored at -80 ℃
(Eggler, 2005; Ogura, 2010).
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When overexpressing Keap1, 20 µL of the media containing pET1b Keap1 plasmid was taken out
of the stock and resuspended in 2 mL of 2x YT media containing 50 µg/mL Carbenicillin as a starter
culture. The starter culture was incubated at 37 ℃ overnight. Then the 2 mL culture was directly added
to 200 mL LB media with 50 µg/mL Carbenicillin per 1-litre LB growth of bacteria. The 200 mL LB
was grown overnight at 37 ℃. After the overnight growth, the bacterial cells were pelleted by
centrifugation (6, 000 xg, 15 mins, room temperature, Avanti rotor JLA-16, 250) and were resuspended
into 1 L of LB media containing 50 µg/mL Carbenicillin to reach a starting OD600 of 0.10 - 0.15. The
cell culture was incubated at 37 ℃ until the OD600 reach 0.8-0.9. The Keap1 overexpression was
induced overnight with 1 mM IPTG (BioShop) at 22 ℃. The cells were later harvested after 18 hrs of
growth with OD600 > 2.0. The bacterial cells were pelleted by centrifugation at 6,000 xg for 20 mins in
a Beckman JLA-9.1000 rotor. The pellets were washed with 1 x Dulbecco’s Phosphate Buffered Saline
(PBS) and collected by centrifugation at 6, 000 xg for 20 mins in a Beckman JA 30.50 rotor, then stored
at -20 ℃ until needed.

2.1.2.2 Purification of recombinant Human Keap1
Bacterial cells were thawed in 37 ℃ water bath and resuspended in 30 mL/g of Lysis buffer (50
mM Tris-HCl, 150 mM NaCl, 5 mM MgSO4, pH 8.0 – 9.0). The suspension was mixed with 2 scoops
of human lysozyme and incubated in 37 ℃ water bath for up to 30 mins. The suspension was then
subjected to lysis by Avastin Homogenizer. The product after lysis was mixed with protease inhibitor,
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100 µL PMSF per 10 mL of suspension and was adjusted with imidazole stock (1 M) as well as NaCl
stock (5 M) to binding buffer (50 mM Tris-HCl, 500 mM NaCl, 10 mM Imidazole, pH 7.8)
concentrations. Cellular debris and protein precipitation were removed by centrifugation at 40, 000 xg
in JA 30.5 rotor at 4 ℃ for 30 mins. The resulting supernatant was adjusted to pH 7.8 using 1 N HCl
stock and was then combined with 15 mL of binding buffer equilibrated Ni-Sepharose beads and
incubated at 4 ℃ for about 2 hrs. The Ni-sepharose beads were poured back into a 50 mL column and
washed by gravity using 150 mL of binding buffer followed by 500 mL wash buffer (50 mM Tris-HCl,
500 mM NaCl, 20 mM Imidazole at pH 7.8). The bound Keap1 was eluted over a 30 mins duration with
5 mL fractions by gravity flow with elution buffer (50 mM Tris-HCl, 500 mM NaCl, 750 mM Imidazole
at pH 7.8). Protein containing fractions were determined by qualitative BioRad assay and pooled
together. The eluted protein solution was desalted through being dialyzed in 2 L dialysis buffer (20 mM
Hepes, 100 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine/TCEP at pH 7.5) using a Spectra/Por 6
dialysis tubing with a molecular weight cut-off (MWCO) of 30 kDa overnight and then another 4 hrs.
The dialyzed protein sample was centrifugated to remove precipitation (40, 000 xg, 15 mins, at 4 ℃).
Then the protein sample was filtered through a 0.20 µm low protein binding membrane filter (Pall)
before further purification process. The purified Keap1 protein sample fractions were analyzed by SDSPAGE using 8 % gels with Coomassie Brilliant Blue R-250 staining. The purified Keap1 protein sample
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was subjected to a BioRad assay to determine the protein concentration and was used for further
experiments.

2.1.3 Preparation of recombinant Human Hsp90β
2.1.3.1 Overexpression of recombinant Human Hsp90β
The pET28a hHSP90β was transformed into Escherichia coli BL21 (DE3) cells (Novagen) and
stored at -80 ℃. When doing a 1 L growth, bacteria were resuspended in 2 mL of 2x YT media
containing 35 µg/mL Kanamycin as a starter culture. The starter culture was incubated at 37 ℃ for 5
hrs. Then the 2 mL culture was directly added to 200 mL LB media with 35 µg/mL Kanamycin per 1 L
LB growth of bacteria. The 200 mL LB was grown overnight at 37 ℃. After the overnight growth, the
bacterial cells were pelleted by centrifugation (6, 000 xg, 15 mins, room temperature, Avanti rotor JLA34

16, 250) and were resuspended into 1 L of LB media containing 50 µg/mL Carbenicillin to reach a
starting OD600 of 0.09 - 0.12. The cell culture was incubated at 37 ℃ until the OD600 reach 0.8-0.9. The
Hsp90β overexpression was induced overnight with 0.5 mM IPTG (BioShop) at 22 ℃. The cells were
later harvested after 18 hrs of growth with OD600 > 2.0. The bacterial cells were pelleted by
centrifugation at 6,000 xg for 20 mins in a Beckman JLA-9.1000 rotor. The pellets were washed with
1 x Dulbecco’s Phosphate Buffered Saline (D-PBS) and collected by centrifugation at 6, 000 xg for 20
mins in a Beckman JA 30.50 rotor, then stored at -20 ℃ until needed.

2.1.3.2 Purification of recombinant Human Hsp90β
Bacterial cells were thawed in 37 ℃ water bath and resuspended in 30 mL/g of Lysis buffer (50
mM NaH2PO4/Na2HPO4, pH 8.0 – 9.0). The suspension was mixed with 2 scoops of human lysozyme
and incubated in 37 ℃ water bath for up to 30 mins. The suspension was then subjected to lysis by
Avastin Homogenizer. The product after lysis was mixed with protease inhibitor, 100 µL PMSF per 10
mL of suspension and was adjusted with imidazole stock (1 M) as well as NaCl stock (5 M) to binding
buffer (50 mM NaH2PO4/Na2HPO4, 400 mM NaCl, 6 mM Imidazole, pH 7.8) concentrations. Cellular
debris and protein precipitation were removed by centrifugation at 40, 000 xg in JA 30.5 rotor at 4 ℃
for 30 mins. The resulting supernatant was adjusted to pH 7.8 using 1 N HCl stock and was then
combined with 10 mL of binding buffer equilibrated Ni-Sepharose beads and incubated at 4 ℃ for
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about 2 hrs. The Ni-sepharose beads were poured back into a 50 mL column and washed by gravity
using 150 mL of binding buffer followed by 500 mL wash buffer (50 mM NaH2PO4/Na2HPO4, 400 mM
NaCl, 20 mM Imidazole at pH 7.8). The bound Hsp90β was eluted over a 30 mins duration with 5 mL
fractions by gravity flow with elution buffer (50 mM NaH2PO4/Na2HPO4, 400 mM NaCl, 300 mM
Imidazole at pH 7.8). Protein containing fractions were determined by qualitative BioRad assay and
pooled together. The eluted protein solution was desalted through being dialyzed in 2 L dialysis buffer
(20 mM Hepes, 100 mM NaCl, 1 mM DTT at pH 7.5) using a Spectra/Por 6 dialysis tubing with a
molecular weight cut-off (MWCO) of 30 kDa overnight and then another 4 hrs.
The dialyzed protein sample was centrifugated to remove precipitation (40, 000 xg, 15 mins, at
4 ℃). Then the protein sample was filtered through a 0.20 µm low protein binding membrane filter
(Pall) before further purification process. The His-tag of Hsp90β was not cleaved because it becomes
unstable after the cleavage. The eluted protein was passed through the Superdex 10/300 GL 200
column (GE Healthcare) while being exchanged into 20 mM Hepes, 100 mM NaCl, 1 mM DTT at pH
7.5. The purified Hsp90β protein sample fractions were analyzed by SDS-PAGE using 8 % gels with
Coomassie Brilliant Blue R-250 staining. The purified Hsp90β protein sample was subjected to a
BioRad assay to determine the protein concentration and was used for further experiments.
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2.1.4 Preparation of recombinant mouse STIP1
2.1.4.1 Overexpression of recombinant mouse STIP1

The pDEST17 plasmid (Invitrogen) TEV-STI in E. coli BL21 pLysS was added to 2 mL of 2x
Yeast Extract Tryptone (2x YT) with 50 ug/mL Carbenicillin and 34 µg/mL Chloramphenicol as
starting culture. The starting culture was grown, shaking at 37 ℃ for 5 hrs. 500 mL of LB (with 1 mL
Micronutrients and 1.5 mM MgCl2) was inoculated with 4 mL of the starter cultures and grown
overnight at 37 ℃. The next morning, the overnight culture was centrifuged and resuspended in fresh
LB media (with 1.5 mM MgCl2, 1 mM Micronutrients, 50 ug/mL Carbenicillin, 17 ug/mL
Chloramphenicol) and set up 1 L LB at starting OD600 of 0.18. When the OD600 reached above 1.0, 4 hs
later, the temperature was decreased to 22 ℃, and 1 mM of IPTG was added. The cultures were
incubated overnight for 20 hrs before they were harvested by centrifugation. Pellets were washed with
PBS then stored at -20 ℃ yielding a total of 6.4g wet weight from 2 L.
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2.1.4.2 Purification of recombinant mouse STIP1

Typically, 3 g of bacteria, representing 1 L were resuspended in steps with 30 mL of Lysis
Buffer (50 mM Tris, 100 mM NaCl, 1 mM EDTA pH 8.2) and incubated at 37 ℃ for 15 mins. The
Dounce homogenizer was used to assist complete resuspension and shearing of DNA. ½ of a Protease
Inhibitor tablet (w/o EDTA) was added before lysis with the Avastin homogenizer. Following three
passes through the Avastin homogenizer, the lysate was adjusted with Imidazole stock (1 M) and NaCl
stock (5 M) to 10 mM and 300 mM final concentrations respectively, followed by pH adjustment to 7.6
with 1 N HCl. The lysate was clarified by centrifugation at 32,000 xg for 30 mins at 4 ℃. The
supernatant was combined with 10 mL of equilibrated Ni-Sepharose beads (Binding buffer) and
incubated at room temperature (22 ℃) for ~ 2 hrs. The Ni-sepharose was poured back into a large
column and washed by gravity with 150 mL of Binding Buffer (25 mM Tris, 300 mM NaCl, 10 mM
Imidazole, pH 7.8), followed by 200 mL of Wash Buffer (25 mM Tris, 300 mM NaCl, 20 mM Imidazole,
pH 7.8). Bound protein was eluted over a 30 mins duration with 5 mL fractions by gravity flow with
Elution buffer (25 mM Tris, 300 mM NaCl, 1 M Imidazole pH 7.8). Protein containing fractions
determined by Qualitative BioRad assay were pooled together and dialyzed at 4 ℃ in 12 K MWCO
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Spectra Por 2 overnight against Dialysis Buffer I (20 mM Hepes, 100 mM NaCl, 1 mM DTT at pH 7.5).
The dialysis buffer was changed the next morning and continued for 3 hrs. After removing the sample
from dialysis, the protein concentration was determined (BioRad Assay: 100 mg). 5 mg of His-tagged
Tobacco Etch Virus (TEV) protease was added to remove the Histidine tag overnight at 22 ℃. And the
proteins were analyzed by SDS-PAGE (8 %).

The following day, the protein sample was filtered (0.8 µm), and the Imidazole concentration
was adjusted to 10 mM final with 1 M Stock and 300 mM NaCl with 5 M stock. To remove un-cleaved
protein and Histidine tag, the sample was cycled three times through 5 mL of equilibrated Ni-sepharose
beads (Binding buffer) over a 30-minute duration. The unbound protein was dialyzed into 20 mM Hepes
pH 7.4, 150 mM NaCl for 6 hours, refreshed and then overnight. After dialysis, the protein sample was
filtered with 0.8 µm and 0.45 µm filters, and a BioRad assay revealed a typical final concentration to
be 2.5 mg/mL with a yield of ~70 mg for a 1-liter LB media growth.
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2.2 Nuclear Magnetic Resonance (NMR) Spectroscopy

All NMR experiments were performed on Varian Inova 600-MHz spectrometers (UWO
Biomolecular NMR Facility) at 25 °C in 50 mM sodium phosphate, 100 mM NaCl, 1 mM DTT, and 10
% (v/v) D2O (Cambridge Isotope Laboratories). All NMR data were processed with NMRpipe
(Delaglio et al., 1995), and the spectra were analyzed with NMRviewJ (Johnson, 2004). For the NMR
experiments, 650 L of 50 M 15N-labelled Kelch was combined with 650 L of 0 M, 25 M, 50 M,
and 100 M Hsp90 at 1:0, 1:0.5, 1:1 and 1:2 molar ratio (Kelch: Hsp90) point was reached. 1H-15N
HSQC spectra were collected for each sample combination.

2.3 Isothermal Titration Calorimetry

The ITC experiments were performed on a MicroCalTM VP-ITC. The protein samples
were dialyzed into 50 mM sodium phosphate, 100 mM NaCl, and 1 mM DTT at pH 7.0 or 20
mM Hepes buffer. For the titrations, purified degased Kelch and Hsp90β were prepared to 600 µM and
25 µM, respectively. Kelch was loaded into the 1.36 - mL cell and Hsp90β was loaded into the syringe
(600 µL). Titrations were performed at 4 °C starting with an initial injection of 3 µL, followed by 29
injections of 5 µL, with a spacing of 200 s. The sample cell was stirred at 300 rpm throughout the
experiment. The buffer blank was performed under the same condition and showed negligible heats of
binding. All protein concentrations were determined using Bradford assays.
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2.4 Fluorescently labeling proteins

Purified Proteins such as STIP1, Keap1, Hsp90β, Kelch were subjected to fluorescein labeling
according to the experiment design. About 0.5 mg of Fluorescein-5-Maleimide dye Invitrogen F150
(Thermo Fisher Scientific) was dissolved in 100 µL DMSO as dye stock for the protein fluorescence
labeling process. Protein samples were mixed with TCEP at 100 µM and incubated for about 15 mins
at room temperature (22 °C) to reduce the intra- and inter-cellular disulfide bonds. Then per 1 mL of
the 100 µM reduced protein sample was mixed with 3 µL of the 100 µM fluorescein dye stock to reach
a dye concentration of 0.3 µM. The mixture of protein sample was incubated for up to 2 hrs at room
temperature (22 °C) in the dark. After incubation, the labeling reaction was quenched with 23.8 mM 2Mercaptoethanol/β -Me and transferred into 12-14 kDa MWCO dialysis tubing to be dialyzed against
2 L Hepes buffer (20 mM Hepes, 100 mM NaCl, 23.8 mM β -Me, pH 7.4) for overnight and refreshed
buffer for another 4 hrs in the dark.

The next day, the dialyzed protein sample was collected and loaded to the PD10 column to complete
the removal of unreacted dye. 0.5 -1 mL fractions were collected and subjected to readings at the
absorbance of 280 nm to check the protein amount. And the protein concentration and dye labeling
efficiency were calculated according to Thermo scientific dye manual:

Protein Concentration (M)

=

Absorbance at 280nm−(Absorbance at 495nm x CF)
ε
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CF = Correction factor =

Absorbance at 280nm
Asorbance at 495nm

= 0.3000

ε = protein molar extinction coefficient = 68,000 M-1 cm-1

Moles fluorescein per mole protein =

Absorbance at 495nm
ε x protein concentration (M)

The final labeled protein concentration was also determined with Bio-Rad protein assay to double-check
the calculation. And the fluorescently labeled protein samples were used for protein-binding assay for
fluorescein readings.

2.5 Protein – Binding Assay
All protein-binding assay was performed using Falcon 96-well black polystyrene plates. All purified
protein samples were in 20 mM Hepes, 100 mM NaCl, and 1mM MgCl2 at pH 7.4. The 96-well black
polystyrene plates were treated with 100 µL poly-L-lysine per well to pre-coat the wells for 30 mins at
37 °C to ensure the protein can be better immobilized onto the wells. Prepared unlabeled protein
(usually at 2 µM or 20-25 µg in 100 µL volume) were incubated in the wells overnight at 4 °C or for
30 mins at 37 °C. After the unlabeled protein was immobilized, the excessive protein was flicked off
into the sink. The non-specific sites on the wells that were blocked with blocking solution (1 % gelatin,
100 mM glycine in 1 x PBS) for 1 hr at room temperature (22 °C). After blocking, the wells were
subjected to 1 x T-PBS (0.05 % Tween) wash for three times. And then the plate was incubated with
increasing concentrations of fluorescently labeled proteins (for example, STIP1, Hsp90β, Kelch and
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Keap1) for 1 hr at room temperature (22 °C). Then the plate was subsequently washed extensively with
1 x T-PBS (0.05 % Tween). Following the wash, the fluorescence signal was measured at excitation and
emission wavelengths of 485/535 nm, respectively.
Upon analyzing the data, we use the following method to estimate the binding affinity of proteinprotein interaction. Referencing the analysis of binding of proteins proposed by Scatchard (1949) and
literature about protein-protein interactions (Berson & Yalow, 1959; Feldman, 1972; Rosenthal, 1967)
Binding between a receptor (R) and a ligand (L) could be represented as:

kon

L+R

⇋

koff

LR

The kinetics of binding between the ligand and receptor are often described by two rate constants,
the estimate association rate constant of ligands binding to the receptor (kon), and the disassociation rate
constant of ligand disassociating from the receptor (koff) (units are M-1 s-1 and s-1). Moreover, Kd is
defined as koff/kon. (Guldber & Waage, 1864; Hulme & Treventhick, 2010; Hunter & Cochran, 2016).
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kon [L] [R] = koff [LR]
Ka =
1
𝐾a

𝑘on
𝑘off

𝑘off

=

=

𝑘on

=

[LR]
[L][R]

[L][R]
[LR]

= Kd

Since the total receptor concentration equals the sum of the concentration of free receptor [R] and
the concentration of bound state [LR] complex,

[R]total = [R] + [LR]
Through rearrange the equations, we can derive the following equation:

[R] total =

[LR]𝐾d
[L]

[LR]
[R] total

=

+ [LR]

[L]
[L]+𝐾d

Since [L] total = [L] free + [LR], we have [L] free = [L] total – [LR]. If we have [R] total < < [L] total, then
we have [LR] < < [L] total. Therefore, we can estimate that [L] total ≈ [L] free. Under this circumstance,
when the fraction bound [LR] and [R]total reach 1/2, which is the midpoint before saturating the binding
between ligand and receptor, Kd equals to the [L] total at this point.
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2.6 Animal Model
2.6.1 WT & △TPR1 Mice
Our collaborator Dr. Marco Prado generously provided both the mouse models generated by the
Prado lab. The STIP1ΔTPR1 mouse line (Lackie et al., in preparation; Razzaq, 2018) expresses hypomorphic
STIP1 lacking the TPR1 domain (Lackie et al., in preparation). This mouse model was initially developed
to investigate the function of the TPR1 domain in molecular chaperone networks, which can provide better
insights into co-chaperone STIP1 in mammals. The STIP1 with the deletion of the TPR1 domain led to a
significant reduction in levels of several Hsp90 co-chaperones and STIP1/Hsp90 client-proteins (Lackie
et al., in preparation; Razzaq, 2018).

2.7 Cell tissue culture
2.7.1 SN56 Cell Line
And the murine Septal Neuronal cell (SN56) provided by Bruce Wainer, Emory University was
used to generate STIP1 knockouts (Lackie et al., in preparation). STIP1 expression was eliminated with
CRISPR-Cas 9 (Clustered Regularly Interspaced Short Palindromic Repeats) editing system. The
optimized CRISPR Design Software (Http://crispr.mitedu/) was used to design guide RNAs for the
mouse STIP1 gene to transfect SN56 cells. Specifically, the gene sequence was STIP1 Top 1:
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5’CACCGGTAGTCTCCTTTCTTGGCGT

3’

and

STIP1

Bottom

1

5’AAACACGCCAAGAAAGGAGACTACC 3’. The guide The SN56 cells were incubated in a complete

median containing 1 mM of dbc AMP (Sigma-Aldrich), a cAMP analog, for 48 hrs.

2.8 Western Blotting

Mice were decapitated, and brains were rapidly excised on ice. The brains were dissected into the
cortex on ice and flash frozen on dry ice before transfer to -80 C. Protein extraction and western blot
were carried out as previously described (Beraldo et al. 2013; Martins-Silva et al., 2011).

Western Blot was done by standard technique after peptide separation on 12 % Tris-tricine SDSPAGE and electrotransfer to polyvinyl difluoride membrane (Beraldo et al., 2013). Protein from mouse
brain tissue, SN56 cells were extracted using RIPA buffer (50 mM Tris, 150 mM NaCl, 1 % Triton X100, 0.5 % Sodium Deoxycholate, 0.1 % SDS, pH 8.0) including protease inhibitors (Protease Inhibitor
Cocktail Set 3-EMD Millimore, Burlington, MA) and phosphatase inhibitors (Phosphatase Inhibitor
Cocktail Set 5-EMD Millimore, Burlington, MA), on ice for 15 mins. Protein extracts were centrifuged
at 12, 000 xg at 4 C for 20 mins and the supernatant was collected and quantified with BioRad protein
assay methods. 5 – 30 µg of total proteins were loaded onto Bolt 4 – 12 % Bis-Tris gel. The antibodies
used were anti-STIP1 (rabbit polyclonal 1:5000, in-house antibody), anti-Keap1 (1:500, ab218815,
Abcam, Cambridge, UK), anti-Actin (1: 10,000, Chemicon, CA) anti-Nrf2 (rabbit polyclonal 1: 1,000,
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PA1828, Boster, Pleasanton, CA). Images were acquired using the FluorChem Q system from Alpha
Innotech and analyzed using the ChemiDoc XRS system software (BioRad).

2.9 Quantitative Real-Time Polymerase Chain Reaction

For Real-Time quantitative PCR (RT-qPCR), the RNA was isolated from the brain tissues of the
STIP1ΔTPR1 and WT mouse line using Aurum Total RNA kit for fatty and fibrous tissue (Bio-Rad,
Hercules, CA, USA). The same method was used to isolate RNA from the tissue culture of SN56-WT
and SN56-STIP1-KO cell line. Quantification and quality analysis of RNA in the extracted samples
was done by microfluidic analysis (Agilent Technologies' Bioanalyzer). First-strand cDNA was
synthesized using the iSCRIPT cDNA SYNTHESIS KIT from BioRad. cDNA was subsequently
subjected to RT-qPCR on a CFX-96 Real-Time System (Bio-Rad) using the iQ SYBR Green Supermix
(Bio-Rad). For each experiment, a non-template reaction was used as a negative control. The gene
sequence used for Keap1 was Top 1: 5’ GGATGGCAACACTGACTCCA 3’ and Keap1 Bottom 1 5’
GTCCCGCTCTGGCTCATATC 3’. The melting temperature for the Keap1 primer was 87.5 ℃. The
gene sequence used for Nrf2 was Top 1: 5’ GGACATGGAGCAAGTTTGGC 3’ and Nrf2 Bottom 1 5’
CCAGCGAGGAGATCGATGAG 3’. The melting temperature for the Nrf2 primer was 82 ℃. Also, the
absence of DNA contaminants was assessed in reverse transcription-negative samples and by melting-
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curve analysis. Relative quantification of gene expression was done with the ΔΔCT method using βactin gene expression to normalize the data.

2.10

Statistical Analysis

Statistical analysis for all Western blots, RT-qPCR, and Protein-binding assay was performed using
GraphPad Prism 5 Software (Version 5.0 for Windows, La Jolla California USA). All results were
expressed as mean +/- standard error (SEM) and analyzed with unpaired t-tests, one-way ANOVA or
two-way ANOVA (when comparing control and experimental conditions in the various immunoblots
and protein-binding assays). Significance levels are indicated using asterisks, where **** is p<0.0001,
*** is p<0.001, ** is p<0.01, * is p<0.05.
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CHAPTER 3: RESULTS
3.1 Preparation of recombinant protein samples
3.1.1 The Kelch Domain of Human Keap1
The protocol to overexpress the Kelch domain of Human Keap1 was established previously in the Choy
lab (Khan, 2014). The growth conditions were optimized in both LB media and M9 minimal media to
achieve the optimal protein expression level. The yield of the bacterial pellet was typically 4 - 5g (wetweight) from a 1-liter LB culture and 3 - 4 g from a 1-liter M9 media culture. By using the purification
procedures described in section 2.1.1.2 in Chapter 2, ~30 mg of Kelch protein could be obtained from a
1-liter LB growth and ~ 25 mg of 15N-labeled Kelch could be obtained from a 1-liter M9 minimal media
culture typically. The result of the SDS-PAGE analysis and the FPLC elution profile shown in Figure 3
demonstrated a single peak representing the pure Kelch protein as the final product.
According to multiple pieces of literature, Hsp90β was often stored in Hepes buffer, which ensured protein
to remain more stable (Kundrat & Regan, 2014; Lorenz et al., 2014; Radli et al., 2017). Therefore, we
decided to dialyze Kelch protein into Hepes buffer for storage at 4 ℃ for future experiments. The protein
stability was also monitored over time. As shown in Figure 4, the Kelch sample remained stable for at
least 7 days at 4 ℃ in Hepes buffer.
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Figure 3. The Purification of the Kelch domain of Keap1. A) 12 % SDS-PAGE Analysis of the process
purification of Kelch following the previously established protocol. Kelch domain of Human Keap1 was
expressed from the plasmid pET15b in E. coli BL21 (DE3) cells with M9 minimal media. Lane 1- Protein
molecular weight ladder; Lane 2- total protein of E. coli collected before overexpressing Kelch; Lane 3total protein of E. coli collected after overexpressing Kelch; Lane 4-total protein from insoluble E. coli;
Lane 5-total protein from soluble E. coli; Lane 6- total proteins that were not bound to Ni-sepharose beads;
Lane 7- total protein size exclusion chromatography; Lane 8-the final purified Kelch. B) Elution profile
from Size exclusion chromatography (HiLoad Superdex75) Slow Flow column (1 mL). Absorbance at
260 nm, 280 nm are shown. One major peak indicated the pure Kelch protein.
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Figure 4. The Protein stability of the Kelch domain of Human Keap1. 12 % SDS-PAGE Analysis of
Kelch domain of Human Keap1 in Hepes buffer (20 mM Hepes, 100 mM NaCl, 1 mM DTT at pH 7.5)
which was used in most of the experiments. Lane 1- Protein molecular weight ladder; Lane 2- purified
Kelch stored at 4 ℃ for 1 day; Lane 3- purified Kelch stored at 4 ℃ for 2 days; Lane 4- purified Kelch
stored at 4 ℃ for 3 days; Lane 5- purified Kelch stored at 4 ℃ for 4 days; Lane 6- purified Kelch stored
at 4 ℃ for 5 days; Lane 7- purified Kelch stored at 4 ℃ for 6 days; Lane 8- purified Kelch stored at 4 ℃
for 7 days.
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3.1.2 Full-length Human Keap1
The procedures used to overexpress and purify human Keap1 was adapted from the published
protocols in the literature (Eggler, 2005; Ogura, 2010). The growth conditions in LB media were
optimized to achieve a higher protein expression level. Using the expression protocol outlined in section
2.1.2.2 in Chapter 2, the yield of the bacterial pellet was typically 6 - 7 g (wet weight) from a 1-liter LB
culture.
Even though the full-length Keap1 could be overexpressed successfully in E. coli, the solubility
of the protein is low. This may be because human Keap1 is a cysteine-rich protein, which contains 27
cysteines. Therefore, the protein is sensitive to oxidation, making it highly unstable and prone to
precipitation (Saito, 2016). This property of Keap1 made the protein challenging to be kept in soluble
form during and after the purification process. The typical yield of Keap1 was ~5.0 mg from 1-liter LB
media growth, and the purified protein was immediately used for experimental purposes due to its
limited stability.
Figure 5 showed the product of purification at each step, and the final product of Keap1 has two
molecular weight indicating two different proteins. We sent the SDS-PAGE gel to MALDI mass
spectrometry analysis to identify these two proteins (MALDI Mass Spectrometry Facility, London
Regional Proteomics Centre, Western University). The result showed that the lower molecular weight
band was the purified Keap1 while the higher molecular weight band was a contaminant. Further
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optimization of the purification protocol is required to reduce the contamination.
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Figure 5. The Purification of recombinant human Keap1. 8 % SDS-PAGE Analysis of purified Keap1:
Lane 1 - Protein molecular weight ladder; Lane 2 - total protein from insoluble E. coli; Lane 3 - total
protein from soluble E. coli; Lane 4 - total protein collected from flow-through after washing beads; Lane
5- total protein collected from first wash of the beads; Lane 6 - the final purified Keap1 (the lower band).
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3.1.3 Full-length Human Hsp90β
The protocols for overexpressing and purifying recombinant full-length Human Hsp90β was
established in the Choy lab and literature (Maciejewski, 2017; Radli et al., 2017). The yield of the
bacterial pellet was typically 4 - 5 g (wet weight) from a 1-liter LB culture.
As shown in Figure 6, Hsp90β was overexpressed in E. coli after IPTG induction. The protein
remained soluble during the purification process. The wash buffer used was effective in removing
contaminated proteins non-specifically bound to the Ni - sepharose beads. As the His-tagged Hsp90β
was eluted off the beads, it was rather pure already. Then the protein was dialyzed to the proper buffer
(20 mM Hepes, 150 mM NaCl, 1 mM MgCl2, pH 7.4) in which Hsp90β was relatively stable. The histag was then removed from Hsp90β by the addition of thrombin.
The final step of purification included passing Hsp90β through a size exclusion column.
Figure 6 B shows the FPLC elution profile. Peak #1 corresponded to ~ 400 - 700 kDa protein, which
was likely to be the aggregated form of Hsp90β as it was prone to aggregation. Peak #2 represented a
protein species of molecular weight ~ 160 - 170 kDa, which matched with the molecular weight of
Hsp90β dimer. Peaks #3 and 4 were proteins species of molecular weight ~ 13 - 35 kDa, which were
likely to be the degraded version of Hsp90β without C-terminal. The SDS-PAGE shown in Figure 6 A
shows that after this final purification step, the Hsp90β was purified to near homogeneity. The typical
yield of Hsp90β was about 6 - 8 mg from a 1-liter LB media culture.
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Hsp90β as a chaperone was prone to aggregation because structurally, it contains a significant
amount of hydrophobic surface areas. Figure 7 showed that Hsp90 becomes significantly degraded after
a 3~5-day period. Because of this, we usually utilize freshly purified Hsp90β that was no more than 3days old for our experiments.
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Figure 6. The Purification of recombinant human Hsp90. A) 8 % SDS-PAGE gel of purified Hsp90:
1- Protein molecular weight ladder; 2- total protein of E. coli collected before overexpressing Hsp90; 3total protein of E. coli collected after overexpressing Hsp90; 4-total protein from insoluble E. coli; 5total protein from soluble E. coli; 6- total proteins that were not bound to Ni-sepharose beads; 7- total
protein size exclusion chromatography; 8-the final purified Hsp90. B) Size exclusion chromatography
(Superdex 200) of Hsp90.
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Figure 7. The Protein stability of recombinant human Hsp90. 8 % SDS-PAGE Analysis of
recombinant human Hsp90 in Hepes buffer (20 mM Hepes, 100 mM NaCl, 1 mM DTT at pH 7.4) which
was used in most of the experiments. The profile shows that Hsp90 degrades much more significantly
starting from the fourth day of being stored at 4 ℃. Lane 1- Protein molecular weight ladder; Lane 2purified Hsp90 stored at 4 ℃ for 1 day; Lane 3- purified Hsp90 stored at 4 ℃ for 2 days; Lane 4purified Hsp90 stored at 4 ℃ for 3 days; Lane 5- purified Hsp90 stored at 4 ℃ for 4 days; Lane 6purified Hsp90 stored at 4 ℃ for 5 days; Lane 7- purified Hsp90 stored at 4 ℃ for 6 days; Lane 8purified Hsp90 stored at 4 ℃ for 7 days; Lane 9- purified Hsp90 stored at 4 ℃ for 8 days; Lane 10purified Hsp90 stored at 4 ℃ for 9 days; Lane 11- purified Hsp90 stored at 4 ℃ for 10 days.
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3.1.4 Full-length mouse STIP1
The overexpression and purification protocols of recombinant full-length mouse STIP1
established in the Choy lab (Maciejewski, 2017) were used to prepare the STIP1 samples. Using the
expression protocols outlined in Section 2.1.4.2 in Chapter 2, the yield of the bacterial pellet was
typically 3 - 4 g (wet weight) from a 1-liter LB culture.
As it was shown in Figure 8, STIP1 was well overexpressed in E. coli. And the protein remains
soluble during the purification process. Results of the SDS-PAGE analysis (Figure 8) shows that after
the final purification step, STIP1 was purified to near homogeneity. The typical yield of STIP1 was
about 70 mg from a 1-liter LB media culture.
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Figure 8. The Purification of recombinant mouse STIP1. 8 % SDS-PAGE Analysis of purified
STIP1: Lane 1- Protein molecular weight ladder; Lane 2-total protein from insoluble E. coli; Lane 3total protein from soluble E. coli; Lane 4-total protein from unbound; Lane 5-total protein eluted; Lane
6- STIP1 after cleavage of His-tag by TEV protease; Lane 7- the final purified STIP1.
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3.2 Hsp90β binds the Kelch domain of Keap1
3.2.1 NMR titrations show that Hsp90β interact with the Kelch domain of
Keap1

In a recent high throughput study of the chaperone-cochaperone-client interaction network in
human cells, Taipale et al. uncovered that many proteins with Kelch domains could associate with the
Hsp90β chaperone complexes. For instance, protein KLHL38 (Kelch-like Family Member 38), which
contains a Kelch domain like Keap1, was found to co-immunoprecipitate with Hsp90β (Taipale et al.,
2014). This finding suggested that proteins belonging to the Kelch-Like family could be a new pool of
clients of Hsp90β. This information also led us to speculate that the Kelch domain of human Keap1
protein is responsible for interacting with Hsp90β. Therefore, we started determining whether Keap1 is
a client of protein of Hsp90β through investigating the interaction between the Kelch domain and
Hsp90β.

NMR spectroscopy is a powerful tool for investigating protein structure and interactions. To
probe the interaction between Hsp90β and the Kelch domain of Keap1, we have performed 1H-15N
Heteronuclear Single Quantum Coherence (HSQC) NMR experiments on 15N-labeled Kelch domain of
Keap1 in the presence of different molar ratios of Hsp90β. 1H-15N HSQC spectrum is frequently referred
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to as the ‘fingerprint’ of a protein. Each peak in the HSQC spectrum represents the backbone amide
moiety of an amino acid in the protein. The chemical shifts and intensity of a peak are highly dependent
on the chemical environment and mobility of that particular residue. Therefore, comparing the HSQC
spectrum of a protein in the absence and presence of a binding partner will allow us to identify the
binding interface with residue-specific resolution (Cala et al., 2014; Meyer & Peters, 2003).

We first started with acquiring the HSQC spectra of the 15N-labeled Kelch domain of Keap1.
This served the purpose of ensuring the Kelch protein we purified was pure and well-folded. Figure 9A)
shows a representative 1H-15N HSQC spectrum of

15

N-labeled Kelch. The spectrum contains well-

dispersed peaks and matches with the spectra of Kelch previously collected by the lab under the same
conditions, indicating that the purified Kelch sample was pure, and the protein adopted a well-folded
conformation (Khan, 2014).

We then proceeded to perform the HSQC experiments on different mixtures of

15

N-labeled

Kelch and unlabeled Hsp90. Even though the Kelch domain of Keap1 is relatively soluble, Hsp90
protein is prone to precipitation. In order to obtain high-quality NMR data of the Kelch-Hsp90
complex, we have performed the HSQC experiments using different protein concentrations, buffer
conditions, and molar ratios of the two proteins. What we found was that Hsp90β could only remain
soluble at a concentration lower than 100 µM in Hepes buffer. Thus, we went further to acquire the
HSQC spectra of 15N-labeled Kelch in the presence of unlabeled Hsp90β at 1:0 (50 µM: 0 µM), 1: 0.5
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(50 µM: 25 µM), 1:1 (50 µM: 50 µM) and 1:2 (50 µM: 100 µM) molar ratios (Figure 10). Notably,
since Hsp90β was not 15N-labeled, it was not visible in the HSQC spectra we collected.

Figure 10 shows that many HSQC peaks of 15N-labeled Kelch diminished significantly as more
and more unlabeled Hsp90β was added. It is noteworthy that the NMR signal intensities a protein
decrease with increasing molecular tumbling time (Frueh et al., 2014; Gell, 2002; Jiang et al., 2017).
Because of this, the NMR signals of a low molecular weight protein are much stronger in intensity
compared to the signals of a high molecular weight protein or complex with the same concentration.
Since Hsp90β exists as a dimer in the native state with a molecular weight of 164 kDa, when a 32 - kDa
Kelch molecule binds to an Hsp90 dimer, it becomes part of a large molecular complex with molecular
weight about 200 kDa. At this molecular weight, the signals coming from the 15N-labeled Kelch become
too weak to be observed. Therefore, the significant reduction in peak intensities of Kelch upon the
addition of Hsp90 indicates the interaction of these two proteins. We should point out that there were
peaks of 15N-labeled Kelch that remained observable even in the presence of two molar ratios of Hsp90.
Based on the chemical shift assignments of Kelch published by the lab previously (Khan, 2013), it
seems that many of these signals were originated from the amino acids in the flexible loops of the Kelch
structure. These loops may remain flexible upon binding Hsp90 .
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In principle, we could also perform HSQC experiments with 15N-labeled Hsp90 and unlabeled
Kelch. However, since Hsp90β exists as a dimer in the native state with a molecular weight of 164 kDa,
it is too large to give NMR spectra with good quality.
1

H-15N HSQC Spectra of 15N-labelled Kelch

domain of Keap1
A)

15N

1H

B)

(ppm)

Figure

64

9

Flexible Loops

(ppm)

Figure 9. The Kelch Structure. A) The two-dimensional 1H-15N HSQC spectrum of 15N-labeled
Kelch domain of Keap1 (250 µM 15N-Kelch, 50 mM Sodium phosphate, 100 mM NaCl, 1 mM DTT, pH
7.0 at 25 ℃). B) Structure of the Kelch domain of human Keap1 (Blue and white represents the flexible
loops; Yellow represents the structured blades of β – propellers). Image from the RCSB PDB
(www.rcsb.org) of PDB ID 6ROG (Sethi, R. et al., 2019).
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1H-15N

HSQC Spectrum of
15N-labelled Kelch (50 µM) with Hsp90
(100 µM)

10

Figure 10. The signal intensity of the

15N-labeled

Kelch domain gradually reduces as an

increasing amount of Hsp90β is added to the solution. A) the 1H-15N HSQC spectrum of 15N-labeled
Kelch domain (50 µM 15N-Kelch, 20 mM Hepes, 150 mM NaCl, pH 7.4, at 25 ℃) B) the 1H-15N HSQC
spectrum of 15N-labeled Kelch domain with partial residues disappeared as they bind to Hsp90β (50 µM
15

N-Kelch, 25 µM Hsp90β, 20mM Hepes, 150 mM NaCl, pH 7.4, at 25 ℃) C) the 1H-15N HSQC spectrum

of 15N-labeled Kelch domain with partial residues disappeared as they bind to Hsp90β (50 µM 15N-Kelch,
50 µM Hsp90β, 20 mM Hepes, 150 mM NaCl, pH 7.4, at 25 ℃) D) the 1H-15N HSQC spectrum of 15Nlabeled Kelch domain with partial residues disappeared as they bind to Hsp90β (50 µM 15N-Kelch, 100
µM Hsp90β, 20 mM Hepes, 150 mM NaCl, pH 7.4, at 25 ℃) All 1H-15N HSQC spectra were processed
and analyzed using NMRpipe, NMRviewJ)
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3.2.2 Hsp90β binds to Kelch domain of Keap1 with a weak affinity
Although our NMR data has shown that Hsp90β interacts with the Kelch domain of Keap1
(Figure 10), the binding affinity of Kelch and Hsp90β cannot be determined. Therefore, we attempted
to determine the equilibrium dissociation constant (Kd), stoichiometry (n), and enthalpy(∆H) of the
interaction of Kelch and Hsp90β through Isothermal Titration Calorimetry (ITC) experiment.
The experiments were performed with purified Kelch and Hsp90 at 300 M and 30 M in
20mM Hepes buffer, respectively. We used the highest concentration of Kelch that allowed it to
remained stable in solution. The ITC profile showed in Figure 11 demonstrated that there was a
significant amount of heat change when titrating Hsp90β to Kelch, indicating the interactions between
these two proteins. However, the binding did not reach saturation.
Therefore, we were not able to determine the Kd, n, or ∆H of their interaction. Nevertheless,
the ITC results indicated that Kelch interacted with Hsp90β with a weak affinity.
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A)

B)

C)

Figure

11

Figure 11. Kelch domain of Keap1 binds to Hsp90 weakly. A) ITC titration profile of Kelch domain
with Hsp90 (10:1 mixture Kelch to Hsp90 at 300 M & 30 M in 20 mM Hepes, 100 mM NaCl, 1
mM MgCl2 buffer, pH 7.4, respectively). B) ITC titration profile of Kelch domain with Buffer (300 M
Kelch combined with 20 mM Hepes, 100 mM NaCl, 1 mM MgCl2 buffer, pH 7.4). C) ITC titration
profile of buffer with Hsp90 (30 M Hsp90 combined with 20 mM Hepes, 100 mM NaCl, 1 mM
MgCl2 buffer, pH 7.4).
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3.2.3 Estimation of the binding affinity between Hsp90β and Kelch domain
of Keap1 using the protein-binding assay
Even though the ITC experiments indicated that Kelch binds to Hsp90β at a weak affinity, the
information we could obtain was limited through ITC. Therefore, we turned to the protein-binding
plate assay, a modified enzyme-linked immunosorbent assay (ELISA). This method required a
shorter experimental time and lower quantities of protein; thus, it is more suitable to be used for
unstable proteins such as Hsp90β, Keap1, and Nrf2. As shown in Figure 12 A, after 16 µg Hsp90β
was immobilized in the plate well surface, increasing quantities of the Fluoresceine-5-Melamide
labeled Kelch protein (800 ng, 1.6 µg, 4.8 µg, 9.6 µg, 16 µg, 48 µg, 96 µg) were added to bind with
the available Hsp90β. The fluorescence signal was measured at the excitation/emission wavelengths
of 485/535 nm, allowing us to quantitively measure the amount of fluorescently labeled Kelch that
was bound to Hsp90β. The results (Figure 12 A) showed that as an increasing amount of fluorescently
labeled Kelch was added, there was an increasing amount of Kelch binding to the available Hsp90β.
On the other hand, as a negative control, the gelatin showed no patterns of increasing quantities of
Kelch binding (Figure 12 B).
However, the saturation of binding between fluorescently labeled Kelch and Hsp90β was not
reached with the concentrations of proteins used, which made it difficult to estimate their equilibrium70

binding affinity. Therefore, we have repeated the protein binding assay with higher concentrations of
fluorescently labeled Kelch. Specifically, the quantities of Kelch that were utilized were 32 µg, 64µg,
128 µg, 256 µg, 320 µg, 512 µg, 640 µg, 768 µg, 896 µg, 1.02 mg, 1.15 mg, 1.28 mg, and 1.6 mg.
As shown in Figure 13 A, at ~240 µM (1.15 mg), the fluorescently labeled Kelch was able to saturate
the binding with 2 µM (16µg) Hsp90β.
Assume that Kelch and Hsp90β has a 1:1 stoichiometric interaction. According to the data
analysis in Section 2.5 of Chapter 2, Kd ~ [Kelch] when Hsp90β was half-saturated. Consequently,
we estimated that the Kd of Kelch binding to Hsp90β was 130 µM.

71

A)

B)

P r o t e in B in d in g A s s a y

im m o b liz e d H s p 9 0  b in d in g t o K e lc h

Im m o b iliz e d G e la t in e b in d in g t o K e lc h
( N e g a t iv e C o n t r o l)
F lu o r e s c e n c e

1000

800
600
400
200

In t e n s ity [ a .u .]

F lu o r e s c e n c e

In t e n s ity [ a .u .]

1000

800
600
400
200
0

0
0 .2 5 0 .5 1 .5

3

5

15

0 .2 5

30

t o ta l K e lc h c o n c e n tr a t io n [  M ]

5

15

30

to ta l K e lc h C o n c e n tr a t io n [  M ]

Figure

12

Figure 12. Plate binding assay of fluorescently labeled Kelch binding to Hsp90 weakly.
(Fluorescence labeling efficiency for Kelch is 20 %) A) The plate assay of Kelch binding to Hsp90. The
fluorescence intensity of fluorescently labeled Kelch (concentration range 0.25 µM to 30 µM) as they bind
to immobilized Hsp90 (2 µM). B) The Negative control of plate assay for Kelch binding to Hsp90. The
fluorescence intensity of fluorescently labeled Kelch (concentration range 0.25 µM to 30 µM) binding to
immobilized blocking buffer Gelatine (4 %).
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Figure 13. Plate binding assay of fluorescently labeled Kelch at high concentration binds to
Hsp90 weakly. (Fluorescence labeling efficiency for Kelch is 20 %) A) The plate assay of Kelch binding
to Hsp90. The fluorescence intensity of fluorescently labeled Kelch (concentration range 10 µM to 360
µM) as they bind to immobilized Hsp90 (2 µM). B) The Negative control of plate assay for Kelch binding
to Hsp90. The fluorescence intensity of fluorescently labeled Kelch (concentration range 10 µM to 360
µM) binding to immobilized blocking buffer Gelatine (4 %).
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Figure 14. Plate binding assay of fluorescently labeled Kelch at high concentration binds to
Hsp90. (Fluorescence labeling efficiency for Kelch is 20 %) The fluorescence intensity of fluorescently
labeled Kelch (concentration range 10 µM to 360 µM) as they bind to immobilized Hsp90 (2 µM). This
binding pattern resembles a sigmoidal binding curve of varying concentrations of Kelch as ligand binding
to the immobilized Hsp90 on plate well surface. We estimated that the Kd of Kelch binding to Hsp90β
was ~ 130 µM.
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3.3 Keap1 as a potential client of Hsp90β
3.3.1 Endogenous Keap1 protein expression showed patterns like Hsp90
client protein levels
The NMR, ITC, and protein-binding assay results presented above clearly showed that the Kelch
domain of Keap1 is capable of interacting with Hsp90. Our next step was to investigate the biological
relevance of this protein-protein interaction. In particular, we want to determine whether Keap1 is a
client of Hsp90 in vivo. As mentioned in Section 1.4 in Chapter 1, STIP1 is an Hsp90 co-chaperone,
which plays a critical role in transferring client proteins from Hsp70 onto Hsp90. Lackie et al. (in
preparation) have demonstrated that many of the Hsp70/Hsp90 cochaperones (FKBP51, CHIP, PPIase
and CypA) and client proteins (glucocorticoid receptor, tau, and GRK2) all have reduced levels of
protein expression in STIP1ΔTPR1 (a mouse model with the TPR1 domain of STIP1 deleted) mouse brain
tissues compared to Wild Type (WT) brain tissues. Following these findings, we tested whether the
Keap1 protein level was affected in the STIP1ΔTPR1 mice.
The protein expression of Keap1 in both STIP1ΔTPR1 and WT mouse brain tissues were
determined by western blotting. Figure 15 D shows the representative blot, and panels B and D represent
the quantification of the western blots. Interestingly, in STIP1ΔTPR1 brain tissues, there was no significant
difference in the expression of endogenous Keap1 between the WT and the STIP1ΔTPR1 mouse line (P75

value = 0.7044).
Next, we investigated the Keap1 expression in SN56-STIP1-KO cells, a neuronal cell line with
STIP1 deleted. Similar to the effects of ΔTPR1, Lackie et al. had demonstrated that the protein levels
of client and co-chaperone proteins, including CypA, Pin1, TDP-43, Glucocorticoid receptor, showed
a reduction by approximately 50% when STIP1 was eliminated from the SN56 cells (Lackie et al., in
preparation). We also observed the reduction of Keap1 protein expression in SN56-STIP1-KO
compared to control cells. Figure 15 D showed the protein expression of endogenous Keap1 reduced
by ~50% as STIP1 was absent in SN56 cells, indicating that Keap1 behaved in the same pattern as many
client proteins of Hsp90β (P-value = 0.0280).
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Figure 15. Protein expression of Keap1 in STIP1ΔTPR1 mouse line & STIP1 SN56 KO cells. A)
Immunoblots showed a similar level of Keap1 in the STIP1ΔTPR1 mouse line. B) Quantification of
Keap1 revealed similar protein levels in WT and STIP1ΔTPR1 mouse line (p=0.7044). C) Immunoblots
showed a decrease in the level of Keap1 in SN56-STIP1-KO cells compared to SN56-WT cells. D)
Quantification of Keap1 showed a 50% reduction of protein levels in SN56- STIP1-KO cells
(p=0.0280). (All quantification had one-way ANOVA & T-tests performed.)
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3.3.2 Endogenous Keap1 requires functional co-chaperone STIP1 to
maintain protein stability
As we observed, Keap1 protein expression reduced in SN56 cells with STIP1 eliminated, we want
to investigate further if the change in protein expression was due to the reduction of mRNA
expression. To this end, we performed real-time quantitative polymerase chain reaction (RT-qPCR)
experiments to determine the mRNA expression of Keap1 in STIP1ΔTPR1 and WT mice as well as
SN56-STIP1-KO and SN56-WT cells (Figure 16). Our data showed that Keap1 mRNA expression
remained similar between STIP1ΔTPR1 and WT mice (P-value = 0.4680), as well as between SN56STIP1-KO and SN56-WT cells (P-value = 0.2091). The results suggest that the reduction of Keap1
protein levels in the SN56-STIP1-KO was not due to a decrease in mRNA expression, but instead,
Keap1 requires functional STIP1 to maintain its protein stability in cells.
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Figure 16. mRNA expression of Keap1 in STIP1ΔTPR1 mouse line & STIP1 SN56 KO cells. A)
Primer Design for Keap1 B) RT-qPCR showed that Keap1 has similar gene expression in WT and
STIP1ΔTPR1 mouse cortical tissue, Sample size (n) =5, Cycle threshold (Ct) =24~25, p = 0.4680. C) RTqPCR showed that Keap1 has similar gene expression in SN56-WT and SN56-STIP1-KO cells, n=5,
Ct = 27~29, p = 0.2091.
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3.4 Keap1 interacting with both Hsp90β and STIP1
3.4.1 Recombinant Human Keap1 interacts to recombinant Human Hsp90β
Inspired by our results on protein and mRNA expression of Keap1 in SN56-STIP1-KO cells,
we perform protein-binding assays to investigate the binding mechanisms of full-length Keap1 with
Hsp90β and STIP1. Similar to the protein-binding assay performed on Hsp90β and the fluorescently
labeled Kelch domain of Keap1, after ~20 µg of Hsp90β was immobilized in the plate well surface,
increasing quantities of the fluorescently labeled full-length Keap1 were added to bind with the
available Hsp90β. As illustrated in Figure 17, Keap1 showed binding activity with Hsp90β at a
concentration as low as at 1 µM. Therefore, we learned that the interaction of Hsp90β with fluorescently
labeled Keap1 was able to be detected even at low concentrations of Keap1. Unfortunately, Keap1
became unstable at a concentration higher than 6 µM. This was likely to be caused by the high number
of cysteines in Keap1, making the protein sensitive to oxidation and prone to precipitate at high
concentration. Because of this limitation, we were not able to estimate the binding affinity between fulllength Keap1 and Hsp90.
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Figure 17. Plate binding assay of fluorescently labeled Keap1 binds to Hsp90 weakly. (Fluorescence
labeling efficiency for Keap1 was 100 %) A) The plate assay of Keap1 binding to Hsp90. The
fluorescence intensity of fluorescently labeled Keap1 (concentration range 1 µM to 16 µM) as they bind
to immobilized Hsp90 (2 µM). B) The Negative control of plate assay for Keap1 binding to Hsp90. The
fluorescence intensity of fluorescently labeled Keap1 (concentration range 1 µM to 16 µM) binding to
immobilized blocking buffer Gelatin (4 %).
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3.4.2 Estimation of the binding affinity between Keap1 and fluorescently
labeled STIP1 using the protein-binding assay
We have performed the protein-binding assays on full-length Keap1 and STIP1. Since Keap1
was found to become unstable at higher concentrations, we decided to immobilize recombinant human
Keap1 to the wells of the 96-well plate, which can avoid having Keap1 at high concentration for the
experiment. We then probe the binding by adding increasing amounts of Fluorescein-5-Melamide
labeled STIP1 to the immobilized Keap1. Specifically, we probed 20 µg unlabeled recombinant human
Keap1 with fluorescently labeled recombinant mouse STIP1 in the following quantities: 26.4 µg, 52.8
µg, 79.2 µg, 105.6 µg, 132 µg, 158.4 µg, 184.8 µg, 211.2 µg, 237 µg, 264 µg, 290.4 µg, 316.8 µg, 343.2
µg, 396 µg, 528 µg, and 594 µg. Figure 18 showed that the fluorescent signal as an increasing amount
of fluorescently labeled STIP1 was added to Keap1, indicating that STIP1 interacts with Keap1.
As shown in Figure 18 A, at 80~90 µM (528 - 594 µg), the fluorescently labeled STIP1 was likely
to saturate the binding with 2 µM (13.8 µg) Keap1. As previously mentioned in Section 2.5 of Chapter
2, the Kd of STIP1 binding with Keap1 could be estimated from the midpoint of the binding curve.
Assuming that STIP1 and Keap1 bound at a 1:1 stoichiometric ratio, we estimated that the Kd of STIP1
binding to Keap1 was ~ 44 µM (Figure 19).

82

A)

B)

P r o t e in B in d in g A s s a y

P r o t e in B in d in g A s s a y

K e a p 1 b in d in g t o S T IP 1

K e a p 1 b in d in g t o S T IP 1

400
300
200
100
0

In t e n s ity [ a .u .]

500

F lu o r e s c e n c e

In t e n s ity [ a .u .]

F lu o r e s c e n c e

500

400
300
200
100
0

0

20

40

60

80

100

0

t o t a l S T IP 1 C o n c e n t r a t io n [  M ]

20

40

60

80

100

t o t a l S T IP 1 C o n c e n t r a t io n [  M ]

Figure

18

Figure 18. Plate binding assay of fluorescently labeled STIP1 binds to Keap1 with high affinity.
(Fluorescence labeling efficiency for STIP1 is 100 %) A) The plate assay of Keap1 binding to
fluorescently labeled STIP1. The fluorescence intensity of fluorescently labeled STIP1 (concentration
range 2 µM to 90 µM) as they bind to immobilized Keap1 (2 µM). B) The Negative control of plate assay
for fluorescently labeled STIP1 binding to Gelatine. The fluorescence intensity of fluorescently labeled
STIP1 (concentration range 2 µM to 90 µM) binding to immobilized blocking buffer Gelatine (4 %).
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Figure 19. Plate binding assay of fluorescently labeled STIP1 at high concentration binds to Keap1.
(Fluorescence labeling efficiency for Keap1 is 100 %) The fluorescence intensity of fluorescently
labeled STIP1 (concentration range 4 µM to 90 µM) as they bind to immobilized Keap1 (2 µM). This
binding pattern showed a pattern of binding saturation at 80-90 µM. As STIP1 being the ligand and Keap1
being the receptor in the case of our experiment, the middle point of the binding curve before reaching
binding equilibrium saturation was about 44 µM, and we estimated that the Kd of STIP1 binding to STIP1
was ~ 44 µM.
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3.5 Nrf2 as a potential client of Hsp90β
3.5.1 Endogenous Nrf2 protein expression showed patterns like Hsp90
client protein levels
While the focus of my work was on the interaction between Keap1 and the Hsp90-STIP1
chaperone system, some preliminary data on Nrf2 have been collected. In particular, we have
investigated the changes in protein level and mRNA expression of Nrf2 in STIP1ΔTPR1 mice and
SN56-STIP1-KO cells. The protein expression levels of Nrf2 in both STIP1ΔTPR1 and WT mouse brain
tissues were determined through western blotting. Figure 20 shows the representative blot and panels.
B - D present the quantification of Western blots. This experiment demonstrated that Nrf2 protein
level decreases as the TPR1 domain of STIP1 were deleted in mouse brain tissue. The experiment
was repeated for more than three times. In STIP1ΔTPR1 brain tissues, the expression of endogenous
Nrf2 decreased by ~ 40% as the TPR1 domain in STIP1 was deleted (P-value = 0.0394). Similarly,
we observed a ~50% reduction of endogenous Nrf2 protein expression as STIP1 was knocked out
from the SN56 cells (P-value = 0.0091). These experiment results indicated that endogenous Nrf2
behaved in the same pattern as many client proteins of Hsp90.
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Figure 20. Protein expression of Nrf2 in STIP1ΔTPR1 mouse line & SN56-STIP1-KO cells. A)
Immunoblots showed a decrease in the level of Nrf2 protein in the STIP1ΔTPR1 mouse line. B)
Quantification of Nrf2 showed a 40 % reduction in STIP1ΔTPR1 mice (p=0.0394). C) Immunoblots showed
a decrease in the level of Nrf2 in SN56-STIP1-KO cells compared to SN56-WT cells. D) Quantification
of Nrf2 showed a 50 % reduction of protein level (p=0.0091). (All quantification had one-way ANOVA
& T-tests performed.)
86

3.5.2 Endogenous Nrf2 requires functional endogenous co-chaperone
STIP1 to maintain protein stability
We have also performed RT-qPCR experiments to check whether the decreases of Nrf2 levels
in STIP1ΔTPR1 brain tissues and SN56-STIP1-KO cells were caused by the reduction of mRNA
expression (Figure 21). The result showed that Nrf2 mRNA expression remained similar between
STIP1ΔTPR1 and WT mouse lines (P-value = 0.6269). Interestingly, the mRNA expression of Nrf2 in
SN56-STIP1-KO cells was elevated compared to SN56-WT cells (P-value = 0.0178). This may
suggest that the SN56-STIP1-KO cells were under oxidative stress, causing an increase in Nrf2
mRNA expression. However, functional STIP1 is required to facilitate Hsp90 to maintain Nrf2
protein stability.
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Figure 21. mRNA expression of Nrf2 in STIP1ΔTPR1 mouse line & SN56-STIP1-KO cells. A)
Primer Design for Nrf2. B) RT-qPCR showed that Nrf2 has a similar gene expression in WT and
STIP1ΔTPR1 mouse cortical tissue, n = 5, Ct = 22~23, p = 0.6269. C) RT-qPCR showed that Nrf2 has
similar gene expression in SN56-WT and SN56-STIP1-KO cells, n = 5, Ct = 23~25, p = 0.0178.
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3.6 Preliminary NMR data on the interaction of Nrf2 with Hsp90β
To probe the physical interaction between recombinant Nrf2 and Hsp901H-15N HSQC NMR
experiments were performed on

15

N-labeled Nrf2 in the absence and presence of unlabeled FL-

Hsp90. Upon the addition of Hsp90, the signals of Nrf2 showed minor chemical shifts, which did
not provide a conclusive result. This data was difficult to obtain due to the unstable nature of Nrf2 at
high concentrations. Repeating the experiments with a higher concentration of Nrf2 and Hsp90 is
challenging due to the low solubility of these two proteins.
Moreover, as an intrinsically disordered protein (IDP), Nrf2 possesses a protein architecture
that lacks a stable tertiary structure. The NMR analysis of IDPs is extremely challenging because
IDPs present a small chemical shift dispersion in NMR spectra (Gibbs et al., 2017). As shown in
Figure 22, proton-detected 1H,

15

N-HSQC spectra of Nrf2 exhibited clustered residue dispersion,

which made it difficult to observe the residue chemical shift changes upon Nrf2-Hsp90 interaction.
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H-15N HSQC Spectra of Nrf2 (30 µM) / Hsp90 (30 µM)

1

Figure

22

Figure 22. The signal intensity of 15N-labeled Nrf2 showed mild residue chemical shift as Hsp90β is
added to the solution. The overlay 1H-15N HSQC spectrum of 15N-labeled Nrf2 by itself and with Hsp90β
(Green: 30 µM 15N-Nrf2; Red: 30 µM 15N-Nrf2 combined with 30 µM Hsp90 in 20 mM Hepes, 100 mM
NaCl, 1 mM MgCl2 buffer, pH 7.4, at 25 ℃; 1H-15N HSQC spectra were processed and analyzed using
NMRpipe, NMRviewJ)
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CHAPTER 4: DISCUSSION
Neurodegenerative diseases cause devastating effects on patients’ health and affect millions of
people worldwide. The prevalence of neurodegenerative disorders is expected to increase as the
population ages, which leads to a considerable increase in the associated socioeconomic impact on
society. Current treatment towards neurodegenerative disease focuses on treating the symptoms but
offers no cure.
The heat shock proteins are known as direct activators of transcription factors that upregulate the
expression of protein chaperones in response to protein misfolding. For example, the Hsp70 and Hsp90
can promote the proper folding and functional activation of proteins as well as targeting misfolded or
aggregated proteins for refolding or degradation (Lackie et al., 2017). Moreover, the HSF1 activity
modulated by Hsp70 and Hsp90 can protect cells from proteotoxicity, and cell death was found to be
impaired in neurodegenerative diseases (Gomez-Pastor et al., 2017). Recently, Heat shock proteins are
also found to interact with crucial proteins such as Tau and Aβ, which are potential targets for
neurodegenerative diseases (Karagoz et al., 2014; Willhelmus et al., 2007). Nrf2, whose activation is
mainly dependent on Keap1 modulation, is shown to have valuable neuroprotective potential through
multiple neurodegenerative disease mouse models (Dinkova-Kostova & Kazantsev, 2017). Recent
studies have demonstrated that Keap1 interacts with Hsp90 (Prince et al., 2015; Taipale et al., 2014).
However, the molecular mechanism and the function of their interactions remain unknown. Preliminary
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yeast-two hybrid experiments performed by Dr. Duennwald and his co-workers have suggested that
Nrf2 and Keap1 can both interact with Hsp90. In our study, we focused on studying Hsp90β based on
previous research data, which utilized Hsp90β.
Here we demonstrate that Hsp90 indeed interacts with Keap1 and modulates its protein stability in
both neuronal cell cultures and mouse models. Moreover, this modulation mechanism depends on a
crucial co-chaperone, STIP1. Our data also indicate that Hsp90-STIP1 modulates the protein stability
of Nrf2. All these findings show possible underlying crosstalk between the Keap1/Nrf2-mediated
antioxidative pathway and the Hsp90/HSF1-mediated heat shock response pathway.

4.1

Keap1 as a client of Hsp90

Hsp70/Hsp90 chaperone machinery plays an essential role in maintaining proteostasis (Lackie et
al., 2017). The ATP-dependent Hsp70 can promiscuously bind to unfolded, misfolded, or aggregated
proteins (Mayer, 2013). This ability to interact with a wide range of polypeptides allows Hsp70 to
facilitate polypeptide to fold at the early stage of protein-folding processes and helps them to maintain
their native conformations (Mayer, 2013). Moreover, Hsp70 can help the refolding of denatured and
aggregated proteins to prevent proteotoxicity (Mayer, 2013).
On the other hand, Hsp90 facilitates protein maturation, stabilizes the proteins that tend to
aggregate and helps to activate proteins at the later stage of the protein-folding process (Lackie et al.,
2017; Picard, 2006; Taipale et al., 2012). These cellular events are crucial for stress regulation, cellular
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development, DNA repair, neuronal signaling, and the maintenance of protein quality (Schopf et al.,
2017; Zuehlke et al., 2017). The Hsp70/Hsp90 chaperone machinery has a large pool of protein
substrates (or clients) (Schopf et al., 2017). Moreover, many of the clients chaperoned by Hsp70/Hsp90
chaperone machinery play essential roles in neurodegenerative diseases (Karagoz et al., 2014;
Wilhelmus et al., 2007; Zhang et al., 2010). For example, the microtubule-associated protein tau, one
of the clients of Hsp90, is known to be associated with Alzheimer’s diseases.
Recent studies have shown about 30 % of human E3 ubiquitin ligases were able to bind to Hsp90
(Taipale et al., 2012). For example, the ubiquitin-like PHD and RING finger domain-containing protein
1 (UHRF1) E3 ubiquitin ligases that were discovered to be Hsp90 clients (Ding et al., 2016). PHD and
RING were essential for the maintenance of DNA methylation and were targeted for degradation by
Hsp90 (Ding et al., 2016). Another E3 ubiquitin ligase called CHIP was found to be a co-chaperone of
Hsp70/Hsp90 chaperone machinery and facilitate the degradation of clients through binding with both
Hsp70 and Hsp90 (Connell et al., 2001; Xu et al., 2002; Kundrat & Regan, 2010). Moreover, an E3
ubiquitin ligase, the Cullin 5 (CUL5) was also found to interact with both Hsp70 and Hsp90 and are
involved in client degradation of Hsp90 (Ehrlich et al., 2009). These pieces of evidence indicated that
many E3 ligases were likely to be involved in Hsp70/Hsp90 chaperone machinery interaction and
facilitate the degradation of Hsp90 clients.
A recent discovery made by Dr. Duennawald showed that Keap1, an E3 ubiquitin ligase that
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functions primarily in inhibiting the activation of Nrf2, was able to interact with Hsp90β through Yeast
Two-Hybrid experiments transiently. Through performing western blotting and co-immunoprecipitation
experiments using the HEK293 cells with transfected HA-Keap1 and FLAG-Hsp90 constructs, Prince
et al. also demonstrated that Keap1 was an interactor of both Hsp90 isoforms, Hsp90α, and Hsp90β
(Prince, 2015).

Our physiological data suggested that Keap1 behaves like a client of Hsp90 in mammalian cells.
The STIP1ΔTPR1 developed by the Prado lab is a mouse line that expresses hypomorphic STIP1 lacking
the TPR1 domain (Lackie et al., in preparation). The deletion of the TPR1 domain led a significant
reduction in levels of several Hsp90 co-chaperones and STIP1/Hsp90 client-proteins, providing a
suitable tool for us to monitor the behaviors of clients of Hsp90 that requires the STIP1-mediated
regulation. Moreover, the murine Septal Neuronal cell (SN56) provided by Bruce Wainer (Emory
University) was used to generate STIP1 knockouts (Lackie et al., in preparation). Using both mouse
tissues, we found that endogenous Keap1 expression was significantly reduced in SN56-STIP1-KO
cells but remained unchanged in STIP1ΔTPR1 mice. The level of Keap1 decreased when STIP1 loss the
ability to transfer clients to Hsp90, which indicated that Keap1 is likely to be clients of Hsp90 and
requires STIP1 to be stabilized by Hsp90. However, the level of Keap1 remained similar in STIP1ΔTPR1
mice, and WT mice indicated that the transfer of Keap1 to Hsp90 might be achieved through regions
other than the TPR1 domain in STIP1. Furthermore, we determined that the gene expression of Keap1
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was the same in STIP1ΔTPR1 mice and SN56-STIP1-KO cells when compared with wild types. This
result indicated that the protein expression change found in Keap1 was due to protein stability instead
of low mRNA production.

In agreement with the data from mice model and cell line, our biophysical data also indicated that
purified recombinant human Keap1 could interact with purified recombinant human Hsp90. Since the
abundance of cysteines in the Keap1 protein structure caused it to be highly unstable, we could not
utilize Keap1 at higher concentrations to examine the binding affinity between Keap1 and Hsp90β.
However, the binding between Keap1 and Hsp90β indeed indicated that Keap1 directly interacts with
Hsp90β. Since the interaction between Keap1 and Hsp90β plays an important role in maintaining Keap1
protein stability, it could directly contribute to the modulation of Nrf2-mediated antioxidative response.
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4.1.1 Keap1 interacts with Hsp90 through the Kelch domain
The quantitative high-throughput assessment of Hsp90 client interactions performed by Taipale et
al. has demonstrated that E3 ligases with Kelch domains showed a highly significant trend in interacting
with Hsp90 (Taipale et al., 2014). We performed NMR Spectroscopy, ITC, and protein binding assay to
characterize the interaction between the recombinant Kelch domain of human Keap1 and human
Hsp90β. Upon binding with Hsp90, the NMR spectra of the Kelch domain of Keap1 showed diminished
peak intensity, minor chemical shift changes, and signal disappearance. The combination of complex
signal changes indicated that indeed, Kelch was interacting with Hsp90. Notably, NMR spectroscopy
studies of larger protein (300-1000 residues) are especially challenging (Frueh, 2014; Jiang &
Kalodimos, 2017). This is because large proteins consist of a larger number of residues tend to display
loss of signals in NMR spectroscopy spectra caused by the broaden signal and lower signal-to-noise
ratios (Frueh, 2014). Therefore, we expected Kelch, the protein with a smaller size, to exhibit a
reduction in signal intensity as it increasingly bound to Hsp90β, the larger protein. Our data showed
that signals from the Kelch domain diminished as an increasing amount of Kelch entered the bound
form with Hsp90β and existed as a large protein complex. This result revealed that human Keap1 could
interact with human Hsp90β through the Kelch domain.
Also, we observed that the signal intensity reduction in NMR spectra was minor even when Kelch
domain monomer and Hsp90β dimer were combined at a monomeric ratio of 1:2. This revealed that a
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Kelch domain was not binding with all the available Hsp90β, which indicated that they interacted at a
weak affinity. This result was consistent with the pattern of client-Hsp90 interaction because Hsp90 has
the nature of interacting with its clients transiently (Taipale et al., 2014).
Furthermore, the residues that showed diminishments in signal intensity, as well as minor changes
in chemical shifts, were found in regions of the Kelch domain that were structurally well-folded. As a
32-kDa protein, the Kelch domain has a highly symmetrical six-bladed β-propeller conformation
formed by β-sheet and flexible loops that remained flexible between β-strands. The loop region of the
Kelch domain appeared to remain flexible upon binding Hsp90β, thus with a signal intensity not
changing as much (Figure 9B). Meanwhile, the intensity of the signals from the structured six-bladed
β-propeller showed gradual reduction as more Hsp90β bound with Kelch to become a large proteincomplex. This indicated that Hsp90β was likely to be interacting with Kelch at the well-folded sixbladed β-propeller region.
In agreement with the NMR results, out ITC data indicated that the Kelch domain interacts with
Hsp90 at a weak affinity. Upon combining purified recombinant Kelch domain of human Keap1 with
purified recombinant Hsp90β to achieve a final approximately 10:1 (monomeric Kelch: monomeric
Hsp90β) molar ratio, there was significant heat change in the solution caused by protein-protein
interaction. However, the binding curve of ITC titration indicated that the binding of Kelch with Hsp90β
did not reach saturation, revealing that the Kelch domain of Keap1 interacted with Hsp90β at a weak
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affinity.
Our protein-binding assay was designed and optimized for studying protein-protein interaction
using a small quantity of protein while allowing us to achieve a high protein-protein ratio difference.
Our data allowed the estimation of Kd being ~ 130 µM. This confirmed that the Kelch domain interacts
with Hsp90β transiently at weak affinity.

4.1.2 Keap1 might bind with Hsp90 through other domains
We compared the binding affinity observed when Kelch domain of Keap1 binding with Hsp90β to
when full-length Keap1 binding with Hsp90β. The unstable precipitation-prone nature of purified
Keap1 caused difficulty for us to estimate the binding affinity between Keap1 and Hsp90β. However,
we were able to obtain the unsaturated binding curve of Keap1 interacting with Hsp90β, and the result
showed that full-length Keap1 gave strong fluorescence signal upon binding with Hsp90β. The reason
for the stronger signal may be caused by higher fluorescence labeling efficiency of full-length Keap1
(100 % labeling efficiency) or that full-length Keap1 interacted with Hsp90β with higher affinity than
Kelch domain itself. As Keap1 exists as a homodimer in the native state, the signals could be stronger
because there were two Kelch domains involved in binding with Hsp90β. However, we also suspected
that Keap1 bound to Hsp90β with higher affinity. This is because Keap1 may bind to Hsp90β through
domains other than Kelch. Through literature, we found that Broad-Complex-Tramtrack-Bric-a-Brac
(BTB) domain, a highly conserved domain that could be found in different proteins, was able to bind
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to Hsp90 through pull-down assay and co-immunoprecipitation (Cai et al., 2014; Manjarrez et al., 2014).
A BTB domain is also found in Keap1. Therefore, we speculate that Keap1 can interact with Hsp90β
through both the Kelch domain and the BTB domain. However, further investigation would be required
to confirm and understand the binding mechanism between the BTB domain and Hsp90β.

4.2

Nrf2 as a client of Hsp90

The identification of clients of Hsp90 through binding sites has been challenging (Schopf et al.,
2017). The structural and functional characteristics of Hsp90 clients encompassed large varieties and
were found to follow nonspecific patterns (Schopf et al., 2017). Moreover, Hsp90-client complexes
have transient and dynamic nature, which had made the journey of identifying Hsp90 clients and
understanding Hsp90-client interaction difficult (Taipale et al., 2014). In addition, the large size of
complexes formed by Hsp90 with clients made NMR studies tough. Therefore, the conventional method
of studying Hsp90-client complexes such as crystallization and NMR spectroscopy are not available
methods for all kinds of clients.
Previous studies suggested that E3 ubiquitin ligases that interact with Hsp90 are involved in the
degradation of Hsp90 clients (Taipale et al., 2014; Schopf et al., 2017). Our data reveal that Keap1, an
adaptor protein of the Cul3-based E3 ubiquitin ligase, interacts and behaves as a client of Hsp90. Since
Keap1 is the primary negative regulator of anti-oxidative stress response transcription factor Nrf2, we
speculated that Nrf2, an intrinsically disordered protein, is also a client of Hsp90. Our collaborator Dr.
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Duennawald found that Nrf2 was also able to transiently interact with Hsp90 through Yeast Two-Hybrid
experiment.
Our data from western blotting utilized the STIP1ΔTPR1 mice model, and the SN56-STIP1-KO cell
line reveals that Nrf2 indeed behaves like other clients of Hsp90. The protein expression level of Nrf2
was reduced significantly in both the STIP1ΔTPR1 mice model and SN56-STIP1-KO cell line. This
suggests that Nrf2 protein stability maintenance depends on the proper functional Hsp70/Hsp90
chaperone machinery. As STIP1 was deleted in SN56-STIP1-KO cell tissue, the transfer of clients from
Hsp70 to Hsp90 was disrupted, leading to a reduction of protein expression of Hsp90 clients (Lackie et
al., 2017). Moreover, the absence of the TPR1 domain in STIP1 also led to decreased protein expression
of client that required the TPR1 domain to be transferred to Hsp90. Furthermore, we determined that
the gene expression of Nrf2 was the same in STIP1ΔTPR1 mice and elevated in SN56-STIP1-KO cells
when compared with wild types. This result indicated that the protein expression change found in Nrf2
was caused by loss of protein stability instead of transcriptome modulation. Our findings revealed that
Nrf2 required the transfer of STIP1 through the TPR1 domain to Hsp90 to maintain protein stability.
We attempted to use NMR spectroscopy to probe the interaction between Nrf2 and Hsp90b.
However, the spectral changes of Nrf2 upon addition of Hsp90β was minor. The intrinsically disorder
nature of Nrf2, as well as the large size of both Nrf2 and Hsp90β, made observing structural changes
upon binding challenging. Further investigation would be required to understand the molecular
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mechanism of Nrf2 interacting with Hsp90β.

4.3

STIP1 is critical for modulating Keap1 and Nrf2 protein stability
Co-chaperones are essential regulators of Hsp90 (Schopf et al., 2017). They can bind to Hsp90

and compete with other co-chaperones or bind to Hsp90 simultaneously and facilitate client
recruitment, client structural stabilization, client folding process, and client functional activation
(Schopf et al., 2017). Several co-chaperones recognize the Met-Glu-Glu-Val-Asp (MEEVD) motif in
the CTD of Hsp90 through the TPR domains (Lackie et al., 2017). One of the crucial co-chaperones
that facilitates the stabilization and maturation of client proteins of Hsp90 is the TPR domaincontaining protein STIP1 (Lackie et al., 2017). STIP1 binds to both Hsp70 and Hsp90, allowing the
client to transfer between the two chaperones (Lackie et al., 2017; Schopf et al., 2017).
STIP1 contains three TPR domains and two DP domains, in which the TPR2A-TPR2B is the
minimal fragment that is required to bind both Hsp70 and Hsp90 (Lackie et al., 2017; Schmid et al.,
2012). STIP1 was shown to be crucial for the activation of clients (Beraldo et al., 2013; Chang et al.,
1997). The lack of STIP1 in mice model was shown to be embryonically lethal indicating the
importance of STIP1 in embryonic development and survival (Chang et al., 1997; Beraldo et al.,
2013; Lackie et al., 2017). Specifically, STIP1’s crucial activity is involved in the maintenance of the
functionality of chaperone networks and modulation of apoptosis as well as cellular resilience
(Beraldo et al., 2013; Lackie et al., 2017).
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Previous studies done by Lackie et al. revealed that STIP1 was a master controller of the
chaperone network that maintained the stability of Hsp90 client proteins through proteostasis instead
of transcriptome modulation (Lackie et al., 2017). We took advantage of the recently generated SN56STIP1-KO cell line as well as the △TPR1 STIP1 mice model to understand the role of Hsp70/Hsp90
chaperone machinery in modulating Keap1 and Nrf2 protein maturation and stability. Our results
revealed that not only the protein stability of Keap1 and Nrf2 was dependent on their interaction with
Hsp90, but also, they required STIP1 activity to modulate their protein stability. Based on these
observations, we speculate that the Hsp90-STIP1 chaperone system modulates the binding of Nrf2
through STIP1. Plate binding assay using Nrf2 with STIP1 will be performed to test this hypothesis.
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4.4

Significance
The understanding of Hsp90-client interaction has been challenging so far (Lackie et al., 2017;

Schopf et al., 2017; Taipale et al., 2012; 2014). This study has established that Keap1 and Nrf2 are
likely to be clients of Hsp70/Hsp90 chaperone machinery that required STIP1 to maintain protein
stability. Moreover, previous research provided evidence that the HSF1 and Nrf2 both mediate
cytoprotective pathways that shared common transcriptional targets, compensatory to each in
mammalian, played essential roles in cellular redox metabolism and modulating mitochondrial
structure and functions (Naidu et al., 2015). These two pathways can be activated by the same
inducers, simultaneously indicating possible crosstalk in their molecular mechanism and functions
(Naidu et al., 2015). Our study provides valuable insight into how Hsp90 and STIP1 proteostasis
modulation of Keap1 and Nrf2 may bridge the Keap1/Nrf2 antioxidative response pathway with the
Hsp90/HSF1 heat shock response pathway. The potential in co-modulating these two pathways could
provide benefits in advancing therapeutic treatments and pharmaceutical drug development to treat
neurodisorders.
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CHAPTER 5: CONCLUSION
5.1

Conclusion
Recent studies increasingly suggested that the Keap1/Nrf2-mediated antioxidative response

pathway played an essential role in protecting neurons against pathological symptoms such as
exacerbated oxidative stress, mitochondrial dysfunction, and chronic neuroinflammation, which were
commonly found in neurodegenerative diseases (Browne et al., 2006; Deshmukh et al., 2017;
Dinkova-Kostova & Kanzatsev, 2017; Johnson et al., 2010; 2015; Neymotin et al., 2011; Ramsey et
al., 2007). Moreover, crosstalk between the Keap1/Nrf2-mediated pathway and Hsp90/HSF1mediated heat shock response pathway was proposed based on indirect evidence such as they shared
transcriptional targets, combated cellular oxidative stress, maintain mitochondrial structure and
functions (Baird et al., 2011; Naidu et al., 2015). Both cytoprotective pathways are essential targets
for neurodegenerative disease prevention and treatment-related treatments.
The results of our works suggest that Keap1 and Nrf2 are both clients of Hsp90. Through studies
using mouse brain tissues and neuronal tissue cell culture, we revealed that the protein stability of
Keap1 and Nrf2 rely on functional Hsp70/Hsp90 chaperone machinery and the client transfer cochaperone STIP1. Moreover, we identified that Keap1 interacts transiently with Hsp90 through the
Kelch domain. We have also shown that Keap1 directly interacts with STIP1. Future studies should
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evaluate the molecular mechanism of interaction between Keap1-Hsp90, Keap1-STIP1, Nrf2-Hsp90,
and Nrf2-STIP1.
Overall, our findings proposed Keap1 and Nrf2 as novel Hsp90 clients, which confirmed the
crosstalk between Keap1/Nrf2-mediated pathway and Hsp90/HSF1-mediated pathway. These
findings could provide valuable information for developing effective treatments for
neurodegenerative diseases.

5.2

Limitation & Future Directions
5.2.1 Molecular mechanism of Keap1-Hsp90 and Nrf2-Hsp90
interaction
Through our research, we elucidated that Keap1 and Nrf2 are likely to be clients of

Hsp70/Hsp90 chaperone machinery, and their protein stability required the involvement of cochaperone STIP1. Further experiments involving co-immunoprecipitating Keap1 and Nrf2 with
Hsp90 in neuronal cell tissues would provide strong evidence that they form endogenous clientchaperone complex.
Additionally, the Kelch domain was Keap1 was determined as the region where Hsp90 bound.
However, our data also indicates that Keap1 may bind Hsp90 with a stronger affinity than the Kelch
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domain alone. Therefore, further investigations should be dedicated to understanding how other
domains of Keap1, such as the BTB domain, interact with Hsp90.
We performed a protein-binding assay using fluorescent dye to elucidate the binding affinity
between proteins. This method depended on cysteines in protein to react with the dye, which can
produce proteins that were not uniformly labeled or has low labeling efficiency. A better fluorescent
labeling method could be helpful for a precise future calculation of binding affinity between proteins.
Further experiments should use individual domains of Keap1, Nrf2, and Hsp90 to understand their
involvement in the binding interface as well as their affinity.
Figures 23, 24, and 25 (Section Supplementary) showed the current progress in purifying truncated
Middle and C-terminal domains of Hsp90β. However, the current protocol encountered difficulties
in separating GST-tag from the purified individual MD and CTD of Hsp90β because GST-tag
unspecifically binds strongly with MD and CTD of Hsp90β. Thus, further optimization would be
required for using them in future experiments.
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5.2.2 The role of STIP1 in transferring Keap1 and Nrf2 to Hsp90
By using protein-binding assays with fluorescently labeled proteins, we were able to show that
Keap1 interacts directly with STIP1. However, the instability nature of full-length Keap1 caused
difficulties in studying Keap1-STIP1 binding using NMR spectroscopy and ITC. To overcome this
barrier, individual domains of Keap1, which may have higher stability and solubility than the fulllength protein, could be used to dissect the molecular basis of the Keap1-STIP1 interaction further.
Even though results suggest that Nrf2 is also a client of the Hsp90-STIP1 chaperone system,
physical interactions of Nrf2 with STIP1 and Hsp90 have yet to be determined. Therefore, future
experiments need to purify individual domains of Nrf2 and using them for protein-protein interaction
studies with STIP1 and Hsp90.
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Figure

23

Figure 23. The overexpression of the Middle domain (MD) and the C-terminal domain (CTD) of
recombinant human Hsp90β. 12 % SDS-PAGE Analysis of overexpression of GST-tagged MD and CTD
of Hsp90β: Lane 1- Protein molecular weight ladder; Lane 2-total protein from pre-induced E. coli for
overexpressing GST-tagged MD of Hsp90β; Lane 3-total protein from post-induced E. coli for
overexpressing GST-tagged MD of Hsp90β; Lane 4-total protein from pre-induced E. coli for
overexpressing GST-tagged CTD of Hsp90β; Lane 5- total protein from post-induced E. coli for
overexpressing GST-tagged CTD of Hsp90β
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Figure 24. The purification of the Middle domain (MD) of recombinant human Hsp90β. 16 %
SDS-PAGE Analysis of overexpression of GST-tagged MD of Hsp90β: Lane 1- Protein molecular
weight ladder; Lane 2-total protein from insoluble E. coli; Lane 3-total protein from soluble E. coli;
Lane 4-total protein from unbound; Lane 5-total protein from first wash; Lane 6- total protein eluted;
Lane 7- the final protein after thrombin cleavage.
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Figure 25. The purification of the C-terminal domain (CTD) of recombinant human Hsp90β. 16%
SDS-PAGE Analysis of overexpression of GST-tagged CTD of Hsp90β: Lane 1- Protein molecular
weight ladder; Lane 2-total protein from insoluble E. coli; Lane 3-total protein from soluble E. coli;
Lane 4-total protein from unbound; Lane 5-total protein from first wash; Lane 6- total protein eluted;
Lane 7- the final protein after thrombin cleavage.
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